

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/083439 A1(51) International Patent Classification⁷: **C12N 15/62,**
15/63, 15/70, 11/00(21) International Application Number:
PCT/TR2003/000019

(22) International Filing Date: 20 March 2003 (20.03.2003)

(25) Filing Language: English


(26) Publication Language: English

(71) Applicant (for all designated States except US): **SABANCI UNIVERSITESI [TR/TR];** Orhanli, 34956
Tuzla-Istanbul (TR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SAHIN, Erinc**
[TR/TR]; Sabanci Universitesi, Faculty of Engineering &
Natural Sciences, Biological Sciences & Bioengineering
Program, Orhanli 34956 Tuzla- Istanbul (TR). **TARALP,**
Alpay [TR/TR]; Sabanci Universitesi, Faculty of En-
gineering & Natural Sciences, Biological Sciences &Bioengineering Program, Orhanli 34956 Tuzla- Istanbul
(TR). **SAYERS, Zehra [TR/TR];** Sabanci Universitesi,
Faculty of Engineering & Natural Sciences, Biological
Sciences & Bioengineering Program, Orhanli 34956
Tuzla- Istanbul (TR).(74) Agent: **ARKAN, Selda; Alfa Patent Ltd. Co.,** Agaciragi
Sokak 7-9, Pamir Apt. No:3, Gumussuyu, 34437 Istanbul
(TR).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: **CIRCULAR RECOMBINANT PLASMID DNA CONSTRUCTS AND THEIR PROTEIN PRODUCTS, METHODS
OF PREPARATION AND IMMOBILISATION OF PROTEINS ON SUPPORT**(57) Abstract: The invention relates to new circular recombinant
plasmid DNA constructs and their protein products, to the use of
said protein products in immobilisation, visualisation and quantifi-
cation of enzymes and proteins on compatible support material. The
invention also relates to a method of preparation and immobilisation
of the protein on a compatible support material, to the immobilised
proteins obtained by said method as well as the use of said immo-
bilised proteins in several applications.

WO 2004/083439 A1

BEST AVAILABLE COPY



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *with international search report*
- *with amended claims*

7/PRTS

CIRCULAR RECOMBINANT PLASMID DNA CONSTRUCTS AND THEIR PROTEIN PRODUCTS,
METHODS OF PREPARATION AND IMMOBILISATION OF PROTEINS ON SUPPORT

The invention relates to new circular recombinant plasmid DNA constructs and their protein products, to the use of said protein products in immobilization, visualisation and quantification of enzymes and proteins on compatible support material. The invention also relates to a method of preparation and immobilisation of the protein on a compatible support material, to the immobilised proteins obtained by said method as well as the use of said immobilised proteins in several applications.

The invention concerns the general fields of recombinant plasmid DNA construction, recombinant protein expression, protein detection and quantification, protein immobilisation, arraying, orientation and applications of immobilised proteins. The general application of immobilised proteins and enzymes has played a central role in the expansion of biotechnology and synthesis-related industries.

For immobilising the proteins the following technologies are currently being used:

- Adsorption technology has the advantage that the protein-surface interaction is non-covalent and thus precludes any potentially disruptive chemical modifications associated with covalent immobilization, affording enzymes that often retain good, albeit perhaps altered biological activity, but with the common disadvantage of leaching of adsorbed enzymes from the surface and being lost in time. Although adsorption has the said disadvantage, other major advantages include rapid and facile preparation of the material.
- Encapsulation technology, like the above said adsorption technology, features many advantages associated with non-covalent protein-surface interactions, particularly the very native-like properties of matrix-enclosed enzymes. In addition, enzymes are easily encapsulated and well retained by the support. A related disadvantage however may be poor substrate accessibility, leading to slowed kinetics or lost apparent activity in the case of large substrates.
- Cross-linking technology features the advantages and disadvantages normally associated with covalent modification, one advantage being that protein is well retained on the support. A typical disadvantage of covalent modification is the possibility of loss of biological function as a result of chemical reaction or conditions imposed during the immobilization protocol. A potential advantage/disadvantage defined by context is the alteration of biological function. In the case of cross-linking technology, another disadvantage is the waste of useful biocatalyst since clumps of enzymes are often bound together, intertwined with the support. Under such conditions, diffusional

limitations may define the effective enzyme concentration to only those residing near the surface. Furthermore, the dynamic mobility of one enzyme may be impeded by virtue of being anchored to a neighbouring enzyme.

- Covalent bonding, like above mentioned cross-linking technology, features the advantage of binding enzyme irreversibly to a surface. The observation of poor or altered activity has introduced modifications to the original method, in which a linker strand separating enzyme and surface imposes a distance constraint, thus restoring much native-like activity with possible exception to site-specific alterations normally associated with covalent modification of protein groups. More often than non-covalent methods, the conditions required to achieve covalent bonding may require harsh conditions that lead to enzyme instability and deactivation.

Applicants refer to Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol. 135 (K. Mosbach, Ed) Academic Press, 1987, NY, Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol.137 (K. Mosbach, Ed) Academic Press, 1988, NY; Immobilisation of enzymes and cells (G.F. Bickerstaff, Ed.) Humana Press, 1997, NJ, USA, Immobilised biomolecules in analysis: A practical approach (T. Cass and F.S. Ligler, Eds) Oxford University Press, 1998, NY. *G.P. Royer (1974) Supports for immobilized enzymes CHEMTECH 4, 699.*

Until now tags have been largely limited to poly-His for the reason that it binds to a surface through a coordinating Ni ion. An exception is the work of Nock et al. (S. Nock, J.A. Spudich and P. Wagner (1997) "Reversible, site-specific immobilisation of polyarginine-tagged fusion proteins on mica surfaces" FEBS Letters 141, 233-238) Nonspecific polymer-surface interactions have been discussed very nicely in B. Jonsson, B. Lindman, K. Holmberg and B. Kronberg, Interaction of Polymers with Surfaces: in surfactant and polymers in aqueous solution, John Wiley and Sons, 1998, NY.

Alignment of proteins on a surface using related methods are also given in Y. Harada, K. Yasuda, S. Nomra, N. Kajimura and Y. C. Sasaki (1998) Vectorially Oriented Fixation of Membrane-Embedded Bacteriorhodopsin onto an Inert Base" Langmuir 14, 1829-1835.

The following technologies are currently applied in biotechnological fields:

- Multiple histidine residues (His-tag) in series have been applied for the selective purification of recombinant proteins. This technology is already being used for chromatographic purification of genetically engineered proteins coupled with nickel bearing columns. Applicants refer to Inouye, S. et al. "Aequorea green fluorescent protein: Expression of the gene and fluorescence characteristics of the recombinant protein" FEBS Letters 341 (1994) pages 227-280.

With explosive developments of the proteomic and genomic era, recombinant proteins are sought in large amounts for research, diagnostic and industrial purposes. While large amounts of various proteins can be produced, much research or applied work has experienced setbacks on the basis of poor purity of proteinaceous starting material. To
5 purify proteins further, a great number of techniques and strategies are being used and developed by scientists. One purification strategy in particular uses the affinity of homo-oligomers or special amino acid sequences to appropriate materials such as metal ion bearing surfaces. In this strategy, the cell lysate is applied onto an affinity material for binding. The non-specific proteins of the organism (which do not have the homo-oligomer
10 tail) are washed away. The recombinant protein, which is of interest for production in higher amounts, is retained by this process and a purification is achieved. Applicants refer to Dyke, Michael W. Van; Sirito, Maro and Sawadogo, Michèle "Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain", Gene, Col.111, Issue 1, 1 Feb. 1992, pages 99-104.

15 Fluorescent proteins are readily being used for identifying the location of proteins in situ by using fusion protein strategies. Applicants refer to Green fluorescent protein: properties, applications and protocols (M. Chalfie, S. Kain, Eds.) Wiley-Liss, 1998, NY; Protein localisation by fluorescence microscopy: a practical approach (VJ Allan, Ed.) Oxford University Press, 2000, NY; Imprint oxford; New York: Oxford University Press, c2000;
20 Oancea, E. et al "Green Fluorescent Protein (GFP)-tagged Cysteine-rich Domains from protein Kinase Cas Fluorescent Indications for Diacylglycerol Signalling in Living Cells "The Journal of Cell Biology, Volume 140, No.3, February 9, 1998, pages 485-498.

Multiple cloning site is a special sequence available in all commercially available plasmids, having the property of being cut by sequence specific enzymes. MCSs are normally used
25 to insert genes in order to clone or express foreign genes in a host organism. Applicants refer to J. Sambrook and D. W. Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.

As the efficiency, selectivity and maximum attainable loading of enzymes upon commercially produced surfaces bear strongly on product performance, much effort has
30 been invested to introduce user-friendly, selective, vectorially orienting and easy-to-quantify methods of immobilisation. However there is up to now no process enabling the direct immobilisation of proteins with facility, ease of detection and quantification.

An aim of the present invention is to provide a two-component system, described by a protein encoded by a recombinant plasmid DNA construct and an activated support

material, which permits the direct immobilisation and purification of enzymes and proteins with unsurpassed facility and ease of detection.

It is also an aim of the present invention to provide a two-component system, which permits easy visual detection and quantification through light emission.

- 5 It is another aim of the present invention to provide a protein encoded by a recombinant plasmid DNA construct permitting to incorporate additional restriction enzyme sites within the multiple cloning site.

- It is another aim of the present invention to provide an immobilisation method, which does not require metal ion unlike established purification methods based on His-tag interactions,
10 the interaction between surface and histidine being a direct interaction.

It is another aim of the present invention to provide a technique that can be extended to any protein tag linked to any expressed protein as long as the surface is designed to bear affinity for it.

- It is another aim of the present invention to provide a novel recombinant plasmid construct,
15 specialised for expression and directional immobilisation of any fusion protein or enzyme, permitting easy visualisation and better quantification upon surfaces.

It is another aim of the present invention to afford orientation and arraying of enzymes along a surface.

- Finally it is an aim of the present invention to provide a large distance separating protein
20 and surface to enable immobilised enzymes to display native-like characteristics, which may prove advantageous in certain cases.

The above aims have been achieved by Applicants invention.

- The invention relates to a ircular recombinant plasmid DNA construct encoding a) a protein tag, b) a visual marker protein, and containing c) a multiple cloning site suitable for
25 insertion of an additional gene, characterised in that the gene sequence encoding the protein tag and the visual marker protein are specifically designed and engineered at the DNA level for respectively a) immobilisation purposes and b) visualisation and quantification purposes at the protein level.

- The protein tag may be chosen from the group containing lysine (lys), histidine (his),
30 tyrosine (tyr), phenylalanine (phe), arginine (arg), glutamic acid (glu), aspartic acid (asp), glutamate, aspartate, asparagine (asn), glycine (gly), glutamine (gln), alanine (ala), valine (val), tryptophan (trp). The protein tag may be a histidine-tag such as a polyhistidine variant, in particular (6X) histidine.

The visual marker protein may be chosen from the group containing fluorescent or phosphorescent proteins. The fluorescent protein may be chosen from the group containing Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP), Yellow Fluorescent Protein (YFP) and Blue Fluorescent Protein (BFP) as well as their variants and/or mutants.

- 5 The multiple cloning site contains restriction enzyme recognition sites. The restriction enzyme recognition site is chosen from the group containing Sac I, Sal I, Hind III, Eag I, Not I. The construct further contains a frame adapter of variable length between the visual marker and protein tag genes.

- 10 The invention also relates to a protein expressed by circular recombinant plasmid DNA construct cited above, wherein in the MCS adjacent to the visual marker, it further contains an additional target protein and in that the tag is suitable to interact directly with appropriate surface pendant groups of a support material. The protein may be a fusion protein.

The invention further relates to the use of the protein, in immobilisation and visualisation of proteins on compatible support material.

- 15 One other aspect of the invention is a method for preparing and immobilising a protein on a support material, said method contains the steps of:

- a) Engineering at the DNA level, in series a protein tag suitable to interact directly with appropriate surface pendant groups of a support material, a fluorescent marker protein for visualisation and quantification purposes at the protein level and a
20 multiple cloning site suitable for insertion of a target protein to be immobilised,
b) inserting the corresponding gene of the target protein to be immobilised into the multiple cloning site;
c) initiating protein expression.
d) Optionally pre-treating the support material;
25 e) Incubating the protein and support material together, wherein the protein is immobilised to the support via specific tag-surface interactions;
f) Washing away the non-specific biomolecules;
g) Optionally quantifying the fluorescence of the visual marker protein;
h) Optionally releasing the target protein.

- 30 The support material is chosen from the group containing polymers, biopolymers, glass and composites containing silicone dioxides, metals and metal oxides, as well as any combination thereof on the microscopic, mesoscopic or macroscopic length scale.

- The support material is preferably chosen from the group containing polymers, silicon dioxides, aluminium oxides, titanium oxides, magnesium oxides, borates, metals and other
35 metal oxides.

The polymers may be chosen from the group containing polyolefins such as polystyrene, polyacrylates, polymethacrylates, polybutylene, polyvinylalcohol and related derivatives, polyvinylchlorides, polyisoprene, polypropylene, polyphenols, polyamides, polyesters, polysulfones, polyethersulfones, polyethersulfides, polyimines, polyethyleneglycols, polypropyleneglycols, polyimides, polycarbonates, polyurethanes,

The polymer surface may be chemically treated to bear various functional groups chosen between carboxyl groups, hydroxyl groups, amino groups, amide groups, ester groups, imide groups, imine groups, mercapto groups, nitro groups, sulfonate groups, phosphate groups, phosphonate groups, cyano groups, sulfone groups, aldehyde groups, epoxide groups, urethane groups, ketone groups, phenolic groups, aromatic groups, alkyl, alkenyl, alkynyl, acyl and aryl groups, silanol groups, silicon oxide groups, siloxane groups, metal hydroxide groups, metal oxide groups, and elemental metals. The support material may be carboxylated polystyrene.

The invention also relates to the immobilised protein construct obtained by the above method, wherein it is covalently or non-covalently bonded to the support material. The immobilised protein construct is non-covalent and yet freely accessible and retained like proteins immobilised in the covalent sense.

Finally the invention relates to the use of the immobilised protein constructs in applications selected from analysis, diagnosis (like in enzyme based diagnostic kits), incubation, storage, sensing, arraying and orienting, catalysis, stabilisation, binding, signal transduction, chemical transformation, implant passivation and surface biocompatibilization, surface activation, purification, detoxification and scavenging.

FIGURES

- Figure 1 is the Schematics of Experimental: Preparation of a recombinant plasmid DNA construct for immobilisation
- Figure 2 shows the Resultant plasmid
- Figure 3 is a scheme of immobilisation
- Figure 4 shows the Successful Immobilisation of the GFPimm protein
- Figure 5 is the graphical representation of well fluorescence
- Figure 6 is the infrared spectroscopic profile of the topmost micron layer of native polystyrene;
- Figure 7 is the infrared spectroscopic profile of the topmost micron layer of oxidized polystyrene, implying the formation of surface hydroxyl and carboxylic acid and possibly ketone functionalities.

DEFINITIONS

- Protocol 1 is from QIAGEN® Plasmid Purification Handbook 12/2002 pages 16-20 "Plasmid or Cosmid DNA Purification using QIAGEN® Plasmid Midi and Maxi Kits".
- 5 Protocol 2 is from QIAquick Spin Handbook 07/2002, pages 23-24 "QIAquick Gel Extraction Kit Protocol using a microcentrifuge"
- Protocol 3 is from QIAprep Miniprep Handbook 03/2002, pages 22-25 "QIAprep Spin Miniprep Kit Protocol using a microcentrifuge".
- Protocol 4 is from Version I 020402 25-0006 of Probond Purification System
10 "A manual of methods for purification of polyhistidine-containing recombinant proteins"
- Sequence listing 1 is the GFP Gene
- Sequence listing 2 is the pETM-11
- Sequence listing 3 is the pETM-ADP.
- 15 Sequence listing 4 is the pGFPuv
- Sequence listing 5 is the pETM-GFP-imm

The term frame adapter refers to the following sequence listing:

1 GTACGCCATG GGAGGCACGG TACCTTGTG

- 20 The term "native-like activity" refers to the activity of an immobilized enzyme which is not diminished significantly when compared to its activity in solution. "Native" in this case refers to solution phase for the enzyme.

The term "recombinant plasmid DNA construct" refers to an artificially constructed circular DNA, combining genes obtained from different organisms in nature, using molecular biology protocols.

- 25 The term "protein encoded by a recombinant plasmid DNA construct" refers to a recombinant protein which is the final product of protein synthesis where the recombinant plasmid DNA construct was used as the template and source of genetic information for the said synthesis.

- 30 The term "MAD peptide coding sequence" refers to a gene on the original pETM-11 plasmid, which was excised to modify the plasmid to provide space for insertion of GFP gene as a part of protocols resulting in the invention.

The term "restriction enzyme recognition site" refers to special sequences at which restriction enzymes cut DNA with a high specificity. Each restriction enzyme specifically cuts at its own recognition site on the DNA being engineered.

The term "expression vector or plasmid" refers to a plasmid specialized for high efficiency protein synthesis of a gene inserted in the expression vector's multiple cloning site.

5 The term "multiple cloning site or MCS" refers to a special sequence designed and artificially constructed on the plasmid, which has a number of restriction enzyme recognition sites together, used to provide open ends for insertion of linear gene fragments in the circular plasmid. Production of open ends is performed by digestion of circular plasmid with restriction enzymes that only cut at their specific recognition sites while combining ends of linear gene and open ends of plasmid is performed by ligation with DNA ligase enzyme.

10 The term "protein expression" refers to synthesis of proteins using genetic information in the gene for the protein.

The term "DNA level" refers to the type of activity, which is designed and/or performed on the gene before protein synthesis has taken place, but is affecting the protein.

15 The term "Visual marker protein" refers to a protein (such as GFP), which can be visualised by its fluorescence after it is excited by a characteristic wavelength of light.

The term "immobilisation" refers herein to protein attached to surfaces via a non-covalent interaction. The classic definition of immobilisation refers to covalent and non-covalent methods whereas the classically used terms referring exclusively to non-covalent binding are adsorption or entrapment. The work herein attempts to contrast the facility and generality of immobilisation using the non-covalent tags against the normal methods based upon covalent linkers.

20

The term "support" refers to any polymeric solid in membrane, particle or wall format, natural or synthetic, porous or nonporous, of organic, inorganic, metallic, or combined composition thereof in the microscopic, mesoscopic or macroscopic length scale, that may or may not be soluble, even transiently under certain conditions, and which bears appropriate surface physico-chemical traits to interact favourably with the fusion protein tag, affording immobilisation. Typical examples of synthetic polymers, out of which composites may also be fashioned, as well as example composites, include, but are not limited to, polyolefins such as polystyrene and related side-chain derivatives such as carboxylated polystyrene, Dowex or chloromethylpolystyrene, polypropylene and side-chain derivatives such as carboxylated polypropylene, polyethylene and related side-chain derivatives, polymethylmethacrylate and related side-chain derivatives such as methyl esters, polyacrylate and side-chain derivatives such as polyacrylamide and polyacrylonitrile, polyethersulfones, polyphenylene, polyphenylenesulfide, polysulfone, graphite and active carbon, polyisobutylene, polyisoprene, polycarbonates, polyphenols

25

30

35

such as resol and Novolac, polyesters such as polyalkanoate and polyethyleneterephthalate, polyamides such as Nylon, polyimides, polyimines, polyvinylalcohols and derivatives, polyethyleneglycol, polyvinylesters, polyethers, polyvinylchloride, polytetrafluoroethylene, polyepoxides, polyurethanes, polychlorotrifluoroethylene, cellulose and nitrocellulose, agarose and related polysaccharides, perfluorinated polymers such as Nafion, silicones, soft glass, borosilicate glass, quartz glass, and other derivatives of silicon dioxide, metal oxides such as iron oxide, titanium dioxide, and aluminum oxide, metal silicates and aluminates such as magnesium silicate and aluminum silicate. Typical examples of natural polymers include, but are not limited to kaolin, diatomaceous earth, sand, volcanic pumas and other inorganics, coal, wood or cellulose, alginic acid, agar, chitin and derivatives, amylose, glycogen, DNA and other polysaccharides, paraffins and triglycerides.

The term "purified" as applied to proteins herein refers to a composition wherein the desired protein comprises at least 80% of the total protein component in the composition. The composition may contain other compounds such as carbohydrates, salts, lipids, solvents and the like without affecting the determination of the percentage purity.

Detailed description of the invention

I. Preparation of a recombinant Plasmid DNA construct for immobilisation

For this preparation reference is made to Figure 1, wherein a) shows a native vector DNA, that is an protein tag coding plasmid, b) shows a native vector DNA encoding the visual marker protein; c) shows the modified protein tag coding plasmid modified for inserting the visual marker protein in correct frame and d) shows the final recombinant vector specialised for immobilisation of any enzyme or protein.

Multiple adjacent histidine residues incorporated into a protein structure have been applied for the selective purification of recombinant proteins by means of a stepwise process in which the His-tag is recognised, the target protein is immobilised, the non-specific biomolecules are washed away, and the target protein is desorbed. A related process is used herein.

Multiple cloning site (MSC) is a special sequence that has the property of being cut by sequence specific enzymes. MCS are normally used to insert genes in order to clone or express foreign genes in a host organism. In Applicants' system, the multiple cloning site may be used in order to introduce the gene for the enzyme to be immobilised. Another approach may be to introduce additional restriction enzyme sites to MCS in order to enhance space availability and insertion combinations for the gene of the enzyme to be immobilised.

A commercially available, protein tag coding plasmid like the pETM-11 given in Seq. List. 2 is purified and digested to excise MAD protein coding sequence, which is the MAD gene (Fig 1a). The expression vector (plasmid) pETM-11 in particular was chosen for the reason that its histidine-rich tag could facilitate the subsequent purification and immobilisation of expressed proteins and direct their surface orientation. pETM-11 also bears a cleavable linker gene which is a DNA sequence coding for a small sequence of amino acids that has a specific chemical reactivity allows controlled cleavage by the addition of the appropriate external agent.

On the other hand a frame adapter having the following sequence listing is synthesised. The frame adapter was designed to code for a special sequence of amino acids (Met-Gly-Gly-Thr) forming a high flexibility region in the immobilisation adapter protein.

1 GTACGCCATG GGAGGCACGG TACCTTGTG

Then the frame adaptor is inserted into the modified plasmid to give a novel pETM-Adp plasmid like the one given in Seq. List. 3 (Fig 1c). Bacteria are transformed for amplification of plasmid and the amplified pETM-Adp plasmid is isolated from bacteria and stored.

Then the stored pETM-Adp plasmid is digested to make it ready for another insertion. On the other hand a commercially available native vector DNA like pGFPuv (encoding the visual marker protein GFP) given in Seq. List. 4 is digested to make it ready for insertion (Fig 1b).

The green fluorescent protein has served to identify the location of other proteins *in situ* by exploiting fusion protein strategies. Although in Applicants' model GFP variant is used, any fluorescent or phosphorescent protein such as Red FP, Yellow FP, Blue FP and/or their variants and mutants can also be used.

The strategy adopted was to fuse the plasmid to a GFPuv (green fluorescent protein) gene followed by a multiple cloning site. In principle, this multiple cloning site can be used to introduce the gene of any protein, barring size constraints. It would follow that the location and loading of immobilised proteins can be conveniently assessed on the basis of fluorescence emitted by the accompanying adaptor protein.

Then the GFPuv gene is inserted into pETM-Adp to give the novel pETM-GFP-Imm plasmid construct like the one given in Seq. List.5. This is the final recombinant vector specialised for immobilisation of any enzyme of protein. Bacteria are transformed for amplification of plasmid and the amplified pETM-GFP-Imm plasmid is isolated and stored.

The novel pETM-GFP-Imm plasmid construct does not contain the gene of enzyme to be immobilised but it is designed for another insertion using multiple cloning site after the visual marker protein. (Figure 2)

Figure 2 shows the final recombinant vector specialised for immobilisation of any enzyme of protein in that it has a special place preserved for the insertion of new restriction enzyme sites and the insertion of gene of the enzyme or any protein to be immobilised.

- 5 The production facilities of this vector as well as the affinity purification techniques of proteins are established and cost-effective. More importantly, the advantages stated herein are not in any way compromised by disadvantages which are exclusive to this particular process.

II. Immobilisation of protein product of recombinant plasmid DNA on a compatible polymer surface

- 10 For this immobilisation reference is made to Figure 3 wherein an enzyme or protein (E) containing a visual marker protein (VM) is bonded through its tag (T) to the surface of a compatible support material (S).

- Bacterial culture of the novel plasmid –pETM-GFP-Imm– bearing expression strains are grown. On the other hand bacterial culture of visual marker protein coding plasmid –
15 pGFPuv– bearing expression strains are grown. Then both bacterial cultures were lysed and GFPuv and protein tag containing GFPimm proteins are purified. For both proteins the sodium concentration is lowered and imidazole is removed by dialysis in preparation of surface binding.

- The surface of the compatible support material is prepared. In this particular case the
20 polystyrene surface is oxidised in preparation for immobilisation. Polymer surfaces have been tailored using chemical methods to bear various functional groups. The carboxyl group in particular has been applied in the reversible/irreversible surface immobilisation of positively charged species as well as hydrogen bonding species.

- GFPimm protein is bound to the surface of a compatible support material. Said compatible
25 support material can be a polymer, a biopolymer, a glass or a metal. A prefabricated surface and complementary tag showing good interaction with the surface is used.

- The green fluorescent protein has served to identify the location of other proteins *in situ* by exploiting fusion protein strategies. Although in Applicants' model a GFP variant is used, any fluorescent or phosphorescent protein such as Red FP, Yellow FP, Blue FP and their
30 variants and/or mutants can be used. These fluorescent proteins can be used even in a combined manner that the different enzymes of the same enzymatic pathway can be immobilised and easily quantified on different regions of the same polymeric support.

Applicants' invention permits to avoid all disadvantages of immobilisation technology while benefiting from the advantages of said technology. In Applicants' system, polyhistidine tag

is used for ionic interaction between their positive charges and negative charge loaded on polymeric surface, the difference being that the interaction between surface and tag is direct as opposed to mediated by a coordinating metal ion.

Unlike established purification methods based on His-tag interactions, Applicants' immobilisation method does not require metal ion, the interaction between surface and histidine being a direct interaction.

Furthermore, Applicants' technique can be extended to any protein tag as long as the surface is designed to bear affinity for it. Similar approach may be applied to other protein tags with appropriate tailored surfaces provided that the tag and the surface have affinity to each other.

Measurements are made to show the binding. The distance separating protein and surface being large in comparison to many immobilisation methods, immobilised enzymes in particular are anticipated to display native-like characteristics.

It is made reference to Figures 4 and 5 wherein Figure 4 shows a photo with an integration time of 190ms and Figure 5 shows its fluorescence in relative fluorescence units.

Before taking the photo of Fig.4, GFPimm and GFPuv of approximately same concentration were incubated during 2 hours and washed 3 times with the appropriate buffer in which binding reaction occurred being different in that rinsing buffer does not contain any form of GFP. After 3 washes with buffer, 25mM sodium phosphate, 250mM NaCl solution (the pH was appropriately adjusted with NaOH), the wells were dried by inverting the well over paper towels and tapping the backs repeatedly.

TABLE

96 Well Plate Assay using Gemini XS fluorometer-dry well readings.

	0MAPS	1MAPS	2MAPS	empty
NoGFP	12,02	19,511	17,073	13,635
GFPpH6	23,96	64,387	62,106	20,444
GFPHispH6	63,792	274,97	443,267	76,069
GFPpH7	15,509	67,949	85,149	22,401
GFPHispH7	233,672	690,85	888,078	145,186
GFPpH8	16,176	78,776	89,982	23,807
GFPHispH8	99,532	250,865	344,894	50,509
EMPTY	12,462	13,748	13,114	13,251

The data of the above table and the Figures verify that GFPimm was selectively immobilised on carboxylated polystyrene at pH 6, 7 and 8 whereas native GFPuv was not similarly retained following repeated washings. Moreover, the data indicates that a non-specific interaction, albeit small in comparison, is still present between GFPimm and native polystyrene. For this reason, the possibility of introducing tyrosine or tryptophan tags is also noteworthy, as they can in principle also bind to the aromatic surface via aromatic-aromatic stacking.

Unlike established purification methods based on His-tag interactions, a difference with the technology herein is that no metal ion is required to enable the immobilisation event. The interaction between surface and histidine is a direct interaction between surface-pendent carboxyl groups and imidazole moieties of the his-tag in the protein.

The reversal of binding is facile in simple species that bear few positive charges. In systems involving much larger, multi-charged molecules such as proteins, the biomolecule is often immobilised by its own inertia. In these situations, proteins may in fact be irreversibly immobilised even though no formal covalent bond is created. This relationship is particularly relevant in the short term but it can revert to a reversible association in time.

Since the distance separating protein and surface is large in comparison to many immobilisation methods, immobilised enzymes in particular are anticipated to display native-like characteristics, which may prove advantageous in certain cases.

Examples of alternative interactions include hydrogen-bonding, hydrophobic interactions such as base stacking and other ionic bondings such as positively charged ammonium sulfates and negatively charged amino acids.

Indeed examples of such interactions have been established, however, the notable difference with the proposed technology herein is that the tag is specifically designed and engineered on the protein at the DNA level.

Fusion proteins potentially represent very common products of this technology. Proteins fused to GFPimm will feature a facile means of visualisation in addition to a facile means of purification. In applicants system GFP is used in order to visualise final location and quantify the immobilised enzyme that is fused to the fluorescent protein genetically.

Applicants' novel recombinant plasmid technology specialised for fusion protein expression and immobilisation, permits easy visualisation and better quantification upon surfaces. Fusion proteins potentially represent very common products of this technology. Proteins fused to the marker will feature a facile means of visualisation in addition to a facile means of purification.

The immobilisation strategy also required that a substrate surface respond selectively to the his-tag. To this end, Applicants devised several surfaces bearing linkers that could interact covalently or electrostatically with the imidazole functional group.

5 Now it is made reference to figures 6 and 7 wherein figure 6 is the infrared spectroscopic profile of the topmost micron layer of native polystyrene and figure 7 is the infrared spectroscopic profile of the topmost micron layer of oxidized polystyrene, showing the formation of surface hydroxyl and carboxylic acid and possibly ketone functionalities introduced for interacting with protein tag in the designed protein construct.

10 In Figure 7, 1 stands for H-O stretch of alcohol; 2: stands for H-O stretch of carboxylic acid; 3: stands for C=O stretch of carboxylic acid and ketone; 4: stands for C-O stretch of alcohol and carboxylic acid.

15 In summary Applicants' invention includes following advantages: 1) the flexibility to incorporate enzymes or any proteins or additional restriction enzyme sites within the multiple cloning site, 2) the flexibility to incorporate any amino-acid tags, 3) the flexibility to put distance between the surface and the protein, improving the likelihood that native-like activity of anchored proteins is retained; 4) the possibility to achieve spatial orientation of proteins and permit their arraying along a surface, 5) to permit easy visual detection and quantification through light emission and 6) to avoid exposing protein to potentially harmful chemical modifications.

20 Current work is directed at optimising the conditions of immobilisation, quantifying the bound protein, and characterising its function.

The following example is given for illustration purposes and does not restrict or limit whatsoever the invention.

EXAMPLE

25 The Protocols used in the Example:

QIAGEN Plasmid Purification Handbook 12/2002 Plasmid or Cosmid DNA Purification using QIAGEN Plasmid Midi and Maxi kits, pages 16-20.

QIAquick Spin Handbook 07/2002, QIAquick Gel Extraction Kit Protocol using a microcentrifuge", pages 23-24

30 QIAprep Miniprep Handbook 03/2002 "QIAprep Spin Miniprep Kit Protocol using a microcentrifuge", pages 22-25.

Protocol for ProBond Purification System, A manual of methods for purification of polyhistidine-containing recombinant proteins, Catalog no. K850-01, K851-01, K852-01, K853-01, K854-01 from www.invitrogen.com tech_service@invitrogen.com

Plasmids, Enzymes, Chemicals and Experimental Kits**and Buffers Used in the Example :**

- Acetic Acid Riedel-de Haén, Catalog#: 27225, CAS 64-19-7
- Acrylamide: Bis-acrylamide Sigma, Catalog#: A3699, CAS 79-06-1 and 110-26-9
- 5 • Agarose Sigma, Catalog#: A-6138, CAS9012-36-6
- Ammonium persulfate Carlo-Erba, Italy, Catalog#: 420627,
- Ampicillin Sigma, Catalog#: A9518
- Boric Acid Riedel-de Haén, Catalog#: 11607
- BSA (Bovine Serum Albumin) Promega,
- 10 (10X concentrated) supplied with Kpn I, Nco I and Sac I
- Distilled water, sterile, MilliQ filtered Millipore, MilliQ Academic, France
- EDTA Riedel-de Haén, Catalog#: 27248
- Ethanol Riedel-de Haén, Catalog#: 32221
- Ethidium Bromide Merck, Catalog#: OCO28942
- 15 • Frame Adapter Synthesized by SeqLab, Germany (design E. Şahin)
- Glycerol Riedel-de Haén, Catalog#: 15523
- HCl Merck, Catalog#: 100314
- Imidazole Sigma, Catalog#: I-2399
- IPTG Promega, Catalog#: V39517
- 20 • Isopropanol Riedel-de Haén, Catalog#: 24137
- Kanamycin Sigma, Catalog#: K4000
- Kpn I Promega, Catalog#: R634A
- Liquid nitrogen Karbogaz, Turkey
- Luria Agar Sigma, Catalog#: L-3147
- 25 • Luria Broth Sigma, Catalog#: L-3022
- Lysozyme Merck, Catalog#: 1.05281
- Mass Ruler DNA Ladder Fermentas, Catalog#: #SM0393 High Range
- Mass Ruler DNA Ladder Fermentas, Catalog#: #SM0383 Low Range
- 2-Mercaptoethanol Aldrich Chemical Company, M370-1
- 30 • Micro-Spin™ G-25 Columns Amersham Biosciences, Catalog#: 27-5325-01
- Multi-Core™ Buffer (10X) Promega, supplied with Kpn I, Nco I and Sac I
- NaCl Riedel-de Haén, Catalog#: 13423
- NaH₂PO₄ Merck, Catalog#: 106370
- NaOH Merck, Catalog#: 106462

- Native Purification Buffer (5x) for ProBond Composed of Na_3PO_4 and NaCl .
Preparation is given in Protocol 4 section.
- Nco I Promega, Catalog#: R651F
- Nickel Chloride Merck, 806722
- 5 • pETM-11 European Molecular Biology Laboratories, Germany
- pGFPuv Clontech, Germany
- Polystyrene 96-well plate TPP, TP92696
- Polystyrene culture plate TPP, TP93100
- ProBond™ resin Invitrogen, Catalog#: 46-0019
- 10 • Qiagen Midi-prep Plasmid Purification Kit Qiagen, Catalog#: 12145
(All buffers in protocols are included)
- Qiagen Mini-prep plasmid isolation kit Qiagen, Catalog#: 27106
(All buffers in protocols are included)
- Qiagen QIAquick Gel Extraction Kit Qiagen, Catalog#: 28706
(All buffers in protocols are included)
- 15 • RNAase Qiagen, supplied with Qiagen Plasmid Isol. Kits
- Sac I Promega, Catalog#: R606A
- Sodium Dodecyl Sulphate Sigma, Catalog#: L-4390
- T4 DNA Ligase Buffer (10X) Promega, supplied with T4 DNA Ligase
- 20 • T4 DNA Ligase Promega, Catalog#: M180B
- TEMED Sigma, Catalog#: T-7029
- Tris Fluka, Catalog#: 93349
- Tris-Acetate-EDTA Buffer Composed of Tris, acetic acid and EDTA.
For preparation see J. Sambrook and D. W. Russel,
Molecular cloning: a laboratory manual Vol 1-3,
Cold Spring Harbor Laboratory Press, 2001,
Cold Spring Harbor.
- 25 • Tris-Borate-EDTA Buffer Composed of Tris, acetic acid and EDTA.
For preparation see J. Sambrook and D. W. Russel,
Molecular cloning: a laboratory manual Vol 1-3,
Cold Spring Harbor Laboratory Press, 2001,
Cold Spring Harbor.
- 30 • Tris-HCl Composed of Tris and HCl. Tris is dissolved to a
given molarity and pH is adjusted with HCl.
- 35 • Urea Merck, Catalog#: 1.12007.2500

Instruments and equipment used in the Example:

	Autoclave:	Hirayama, Hiclave HV-110, JAPAN
	Balance:	Sartorius, BP221S, GERMANY
		Schimadzu, Libror EB-3200 HU, JAPAN
	Centrifuge:	Eppendorf, 5415D, GERMANY
5		Hitachi, Sorvall RC5C Plus, USA
	Deepfreeze:	-80°C, Kendro Lab. Prod. Heraeus Hfu486 Basic, Germany
		-20° C, Bosch, TURKEY
	Dialysis tubes	CelluSep T3, Membrane Filtration Products Inc., USA
	Distilled Water:	Millipore, Elix-S, FRANCE
10		Millipore, MilliQ Academic, FRANCE
	Electrophoresis:	Biogen Inc., USA
		Biorad Inc., USA
	Filter membranes	0.2 µm filter: Millipore, Catalog# GNWP04700, USA
		0.45 µm filter: Millipore, Catalog# HNWP04700, USA
15	Fluorometer:	SPECTRAMax GEMINI XS, Molecular Devices Corporation, USA
	FPLC	ÄKTA FPLC, Amersham Biosciences
	FPLC Column	MonoQ Ion Exchange Chromatography Column (10/10), Amersham Biosciences
	Gel Documentation:	UVITEC, UVIdoc Gel Documentation System, UK
20		Biorad, UV-Transilluminator 2000, USA
	Heater Block:	Bioblock Scientific, FRANCE
	Ice Machine:	Scotsman Inc., AF20, USA
	Incubator:	Memmert, Modell 300, GERMANY
		Memmert, Modell 600, GERMANY
25	FT Infrared Spectrometer:	Equinox 55 TGA-IR, Bruker Optics Inc.
	with Attenuated Total Refl. Accessory	
	Laminar Flow:	Kendro Lab. Prod., Heraeus, HeraSafe HS12, GERMANY
	Magnetic Stirrer:	VELP Scientifica, ARE Heating Magnetic Stirrer, ITALY
		VELP Scientifica, Microstirrer, ITALY
30	Microliter Pipette:	Gilson, Pipetman, FRANCE
		Mettler Toledo, Volumate, USA
	Microwave Oven:	Bosch, TURKEY
	pH meter:	WTW, pH540 GLP MultiCal®, GERMANY
	Polystyrene 96-well plate	TPP, SWITZERLAND
35	Power Supply:	Biorad, PowerPac 300, USA
		Wealtec, Elite 300, USA
	Refrigerator:	+4° C, Bosch, TURKEY

	Shaker:	Forma Scientific, Orbital Shaker 4520, USA
		GFL, Shaker 3011, USA
		New Brunswick Sci., Innova™ 4330, USA
	Sonicator	Vibracell 75043, Bioblock Scientific, FRANCE
5	Spectrophotometer:	Schimadzu, UV-1208, JAPAN
		Schimadzu, UV-3150, JAPAN
		Secoman, Anthelie Advanced, ITALY
	Speed Vacuum:	Savant, Speed Vac® Plus Sc100A, USA
		Savant, Refrigerated Vapor Trap RVT 400, USA
10	Thermocycler:	Eppendorf, Mastercycler Gradient, GERMANY
	Vacuum:	Heto, MasterJet Sue 300Q, DENMARK
	Vortex:	Velp Scientifica, ITALY

Step 1: Preparation of vector for ligation:

15 pETM11 vector originally has a protein (MAD) coding sequence which is removed to modify the vector for using with larger inserts. For this purpose, enzymatic digestion of purified pETM-11 vector was performed using *KpnI* and *NcoI* restriction enzymes.

A: Purification of pETM-11:

XL1-Blue *E.coli* strain containing pETM-11 plasmid was grown in 50 mL Luria Broth with 50 µg/mL final concentration of Kanamycin at 37°C, at 300 rpm overnight.

20 Overnight grown cultures are used for isolation of pETM-11 plasmid by using Protocol 1. Quantification is done by spectrophotometric absorbance measurement at 260 nm by using the formula: [DNA] = [Abs] x 50 ng/µl. The measurement value is verified with gel electrophoresis results.

B: Digestion of pETM-11 with *Kpn I* and *Nco I*:

- 25
- 56 µl pETM-11 vector (~5.6 µg)
 - 8 µl Multi-Core™ buffer system
 - 8 µl BSA
 - 4 µl *Kpn I*
 - 4 µl *Nco I*
- 30 3 hours incubation was performed at 37°C, digestion was verified with agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

MAD coding sequence is removed from pETM-11 by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis following double digestion with *Kpn I* and *Nco I*. Larger fragment (pETM-11 without MAD) was isolated by using Protocol 2. Quantity estimation was done by

35 agarose gel electrophoresis analysis.

Step 2: Preparation of frame adapter for ligation:

The adapter was digested at both sides by *Kpn I* and *Nco I* restriction enzymes in six different Eppendorf tubes in parallel, by using the following protocol:

- 2 µl Adapter (0.025 nmol/µl)
 - 5 • 4 µl Multi-Core™ buffer system
 - 6 µl BSA
 - 2 µl *Kpn I*
 - 2 µl *Nco I*
 - 24 µl dH₂O (MilliQ filtered, sterile)
- 10 Overnight incubation was performed at 37°C, 6 tubes of digests were combined together and desalted by passing two times through Micro-Spin™ G-25 Columns. Digestion verification and quantity estimation is performed by polyacrylamide urea gel electrophoresis (3 mL 30%:0.8% - Acrylamide:Bis-acrylamide; 500 µl 10xTBE; 2.1 gr urea; 1.5 mL dH₂O; 45µl APS; 3 µl TEMED).
- 15 Frame adapter 1 GTACGCCATG GGAGGCACGG TACCTTGTG

Step 3: Ligation:

"pETM-11 without MAD" was ligated with "frame adapter" in order to prepare the vector for insertion of GFP within the right frame of protein synthesis. A wide range of different concentration ratios were applied in order to optimise ligation in this specific case where

20 insert is ~0.1% of the vector. The following protocol was used:

<u>PETM-11 + Adapter</u> <u>(1:0.2 (v:v))</u>	<u>pETM-11 + Adapter</u> <u>(1:0.8 (v:v))</u>	<u>PETM-11 + Adapter</u> <u>(1:10 (v:v))</u>	<u>Self Ligation</u> <u>(control)</u>
1µl pETM-11	1µl pETM-11	1µl pETM-11	1µl pETM-11
0.2 µl Adapter	0.8 µl Adapter	10 µl Adapter	2 µl Ligation buffer
2 µl Ligation buffer	2 µl Ligation buffer	2 µl Ligation buffer	1 µl Ligase
1 µl Ligase	1 µl Ligase	1 µl Ligase	16 µl dH ₂ O
15.8 µl dH ₂ O	15.2 µl dH ₂ O	6 µl dH ₂ O	

Ligations were performed at 25°C overnight.

Step 4: Transformation:

- 50 µl competent *E. coli* XL1-Blue cloning strain was added on overnight ligation mixes.
- 25 • Competent cell added ligation mixes were incubated 20 min on ice.
- Tubes were incubated at 42°C heater block for 3 minutes.

- 900 µl LB (without Kanamycin) was added to each ligation mix.
- LB added transformation mixes are incubated for 1.5 hours at 37°C with 190 rpm shaking.
- 100 µl and 400 µl aliquots were spread on Luria Agar+Kanamycin plates and the plates were incubated at 37°C incubator overnight.

Step 5: Colony Check for Presence of Insert:

5 colonies were picked one by one and grown overnight in 5 mL LB+ Kanamycin cultures individually at 37°C with 300 rpm shaking. Next day, plasmid isolation was performed by application of Protocol 3 to each overnight culture. Each isolated plasmid was digested by either *Kpn I* or *Nco I* under the following conditions:

- 5 µl mini-prep isolated plasmid
- 1 µl Multi-Core™ buffer system
- 1 µl BSA
- 0.5 µl *Kpn I* OR *Nco I* for each mini-prep isolated plasmid
- 2.5 µl dH₂O (MilliQ filtered, sterile)
- Incubation for 3 hours at 37°C.

Digestion efficiency and presence of vector plasmid were detected by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis analysis in which uncut and cut original (unmodified) pETM-11 were also used as standards. The vector was quantified by spectroscopic analysis at UV-visible wavelength range.

Step 5a -80 Stock Preparation:

After the presence of correct plasmids was verified with agarose gel electrophoresis, glycerol stocks of plasmid bearing colonies were prepared by the following protocol:

- To 850 µl overnight grown bacterial culture, 150 µl sterile glycerol was added.
- Mixed by vortexing.
- Frozen in liquid nitrogen.
- Kept at -80°C.

Step 6- Preparation of adapter bearing vector (pETM-Adp) for ligation:

pETM-Adp was prepared for ligation with GFP gene by enzymatic digestion by *Kpn I* and *Sac I* by using the following protocol:

- 37 µl vector (~6 µg)
- 6 µl Multi-Core™ buffer system
- 6 µl BSA
- 2.5 µl *Kpn I*

- 2.5 μ l *Sac* I
- 6 μ l dH₂O

3 hours incubation was performed at 37°C, digestion was verified with agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

- 5 The result of enzymatic reaction was evaluated qualitatively and quantitatively by using agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis. Double digested pETM-Adp was isolated by Protocol 2 and isolated linear pETM-Adp was quantified by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

Step 7- Preparation of insert for ligation:

- 10 GFP coding gene was provided by removing the gene from pGFPuv vector by *Kpn* I and *Sac* I double digestion.

- 56 μ l pGFPuv vector (~5.5 μ g)
- 8 μ l Multi-Core™ buffer system
- 8 μ l BSA

- 15
- 4 μ l *Kpn* I
 - 4 μ l *Sac* I

3 hours incubation was performed at 37°C, quality of digestion was verified and quantity of DNA was estimated by using agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis.

- 20 **Step 8- Ligation:**

Linearized (*Kpn* I and *Sac* I double digested) pETM-Adp vector and GFP insert (*Kpn* I and *Sac* I double digested) were ligated using the following protocol with different concentration ratios between the vector and insert:

<u>pETM-Adp + GFP 1:1 (v:v)</u>	<u>pETM-Adp + GFP 1:12 (v:v)</u>	<u>pETM-Adp + GFP 2:0.2 (v:v)</u>	<u>pETM-Adp + GFP 2:2 (v:v)</u>	<u>pETM-Adp Self ligation</u>
1 μ l pETM-Adp	1 μ l pETM-Adp	1 μ l pETM-Adp	2 μ l pETM-Adp	1 μ l pETM-Adp
1 μ l GFP	12 μ l GFP	0.2 μ l GFP	2 μ l GFP	2 μ l Ligase Buffer
2 μ l Ligase Buffer	2 μ l Ligase Buffer	2 μ l Ligase Buffer	2 μ l Ligase Buffer	1 μ l Ligase
1 μ l Ligase	1 μ l Ligase	1 μ l Ligase	1 μ l Ligase	16 μ l dH ₂ O
15 μ l dH ₂ O	4 μ l dH ₂ O	14.8 μ l dH ₂ O	13 μ l dH ₂ O	

Ligations were performed by incubating above ligation mixes at 25°C overnight.

Step 9- Transformation:

- 50 µl competent *E. coli* XL1-Blue cloning strain was added on overnight pETM-Adp + GFP 1:12; 2:0.2; 2:2; self lig. ligation mixes. 50 µl competent *E. coli* BL21-DE3 expression strain was added on overnight pETM-Adp + GFP 1:1. In addition to
5 above indicated tubes, one transformation control (1 µl uncut pETM-Adp, 19 µl dH₂O), one negative control (50 µl untransformed BL21-DE3) and one positive control (50 µl untransformed BL21-DE3) were prepared in different tubes for spreading on different media.
- Competent cell added ligation mixes were incubated 20 min on ice.
- 10 • Tubes were incubated at 42°C heat block for 3 minutes.
- 900 µl LB (without Kanamycin) was added to each ligation mix.
- LB added transformation mixes are incubated for 1.5 hours at 37°C with 190 rpm shaking.
- 100 µl and 400 µl aliquots of pETM-Adp + GFP 1:12; 2:0.2; 2:2; self lig.; negative
15 control and transformation control tube contents were spread on Luria Agar+Kanamycin plates, pETM-Adp + GFP 1:1 tube content was spread on a plate half of which was enriched with 1 mM IPTG before the colony spreading step; positive control was spread on Luria Agar plate and the plates were incubated overnight at 37°C incubator.

Step 10: Colony Check for Presence of Insert:

- Colonies bearing functional GFP gene was selected by checking fluorescence under UV light source. 3 colonies were picked from both XL1-Blue strain and BL21-DE3 strain containing plates. The picked colonies were grown overnight in 5 mL LB+Kanamycin cultures individually at 37°C with 300 rpm shaking.
- 25 Next day, pelleted bacterial cultures were photographed under UV for fluorescence; plasmid isolation was performed by application of Protocol 3 to each overnight culture. Each isolated plasmid was digested by both *Sac* I and *Nco* I under the following conditions:
- 3 µl mini-prep isolated plasmid
 - 1 µl Multi-Core™ buffer system
 - 30 - 1 µl BSA
 - 0.5 µl *Sac* I
 - 0.5 µl *Nco* I
 - 4 µl dH₂O (MilliQ filtered, sterile)
 - Incubation for 3 hours at 37°C.

Presence of vector plasmid and presence of insert were detected by agarose (1% in Tris-Acetate-EDTA Buffer) gel electrophoresis analysis and quantified by spectroscopic analysis in UV-visible wavelength range.

Step 10a-80 Stock Preparation:

- 5 After the presence of plasmids with inserts were verified with agarose gel electrophoresis, glycerol stocks of plasmid bearing colonies were prepared by the following protocol:
- To 850 µl overnight grown bacterial culture, 150 µl sterile glycerol was added.
 - Mixed by vortexing.
 - Frozen in liquid nitrogen.
- 10 • Kept at -80°C.

Step 11-Expression (Induction of GFP and GFPimm Synthesis):

Starter cultures of GFPuv and GFPimm bearing BL21-DE3 expression strains were grown in 5 mL LB+ Ampicillin (0.1 mg/mL Amp.) and LB+ Kanamycin (0.05 mg/mL Kan.) respectively for 8 hours at 37°C with 300 rpm shaking.

- 15 Absorbance measurements of cultures were performed at 600 nm and starter cultures were diluted to 0.02 OD in 2x250 mL LB+ Ampicillin (0.1 mg/mL Amp.) and LB+Kanamycin (0.05 mg/mL Kan.) in 2x1000mL Erlenmeyer flasks. The cultures were grown overnight at 37°C with 300 rpm shaking.

Step 12-Purification of GFPimm Protein Construct:

- 20 Purification of GFPimm construct was performed by using Protocol 4 with the exception in scaling up so that 40 mL 1x Native binding buffer was used to resuspend bacterial pellet.

Isolated GFP was quantified using spectroscopic analysis for 397 nm wavelength which is characteristic local absorption maximum of GFP. Quantification was verified by Sodium Dodecyl Sulphate – Polyacrylamide gel electrophoresis results.

- 25 **Step 13-Purification of GFPuv Protein:**

40 mL 30 mM Tris-HCl, pH 7.5 + Lysozyme (1 mg/mL) was used to resuspend pelleted bacteria. The bacteria suspension was incubated for 30 min. on ice, then sonicated for 4 min with 10(sec):10(sec) pulse:cooling steps on ice.

Cell debris was precipitated by centrifugation at 17000g for 15 min at 4°C.

- 30 Soluble phase was filtered through 0.45 and 0.22 µm filters respectively. Filtered solution was applied to MonoQ ion exchange column with a linear salt concentration gradient from degassed, 0.22µm filtered, 30 mM Tris-HCl, pH 7.5 to degassed, 0.22µm filtered, 30 mM Tris-HCl, 1 M NaCl pH 7.5 with 0.5 mL/min flow rate.

Isolated GFP was quantified using spectroscopic analysis for 397 nm wavelength which is characteristic local absorption maximum of GFP. Quantification was verified by Sodium Dodecyl Sulphate – Polyacrylamide gel electrophoresis results.

Step 14-Lowering Na⁺ Concentration for Binding Preparation:

- 5 GFPuv and GFPimm proteins were dialysed against 25mM Na₃PO₄; 250 mM NaCl with different pH values (pH 6.0, pH 7.0, pH 8.0) for 6 hours at 4°C. GFP samples were then centrifuged in 2 mL Eppendorf tubes and supernatants were taken in clean Eppendorf tubes. Supernatants were re-quantified for GFP content using spectroscopic analysis and SDS-Polyacrylamide gel electrophoresis.

10 **Step 15-Surface Preparation:**

2 M and 3 M ammonium persulfate solutions were prepared (for 3 M APS preparation, solution must be heated to 45°C)

Polystyrene 96 well plate was filled 2/3 of its well capacity providing lanes for dH₂O, 2M APS and 3M APS. The 96 well plate was tightly closed and incubated for 24 hours at 70°C.

- 15 The plate was rinsed with dH₂O and dried in 70°C.

Note – Infrared spectroscopic evidence given in Figure 6 verified the formation of carboxylic acid functional groups.

Step 16-Binding to Surface:

- 20 After verifying that impurity of GFPuv and GFPimm proteins are comparable, their concentration was equalized by diluting concentrated sample considering data from spectroscopic analysis.

Fluorescence of empty plate was measured by Molecular Devices: SpectraMax GeminiXS Fluorometer.

- 25
- 100 µl of GFPuv and GFPimm containing samples were loaded in wells of 96 well plate in an order from pH 6.0 to pH 8.0. Binding was performed with appropriate buffer with the pH of the sample.
 - Binding was performed by 2 hours incubation at room temperature.

dH₂O 2M APS mod. 3M APS mod.

Blank for Background

GFPuv at pH 6	X	X	X
GFPimm at pH 6	X	X	X
GFPuv at pH 7	X	X	X
GFPimm at pH 7	X	X	X
GFPuv at pH 8	X	X	X
GFPimm at pH 8	X	X	X

Step 17-Measurements:

- Samples were removed from wells of plate and the plate was rinsed 3 times with pipetting 200 μ l appropriate buffer for each well.
- All the liquid was removed from the wells.
- 5 • Fluorescence was measured when the plate was dry.
- The wells were filled with 100 μ l of appropriate binding buffer and fluorescence measurements were repeated.

Photographs of dry and wet cases for GFP bound plates were taken under UV light.

- Life span of the proposed technology is difficult to predict, but it is undeniable that
- 10 molecular biology has become an irrevocable part of the basic sciences and therefore a potential market for protein products is unrelenting. Areas of use or application may be analysis, incubation, storage, catalysis, stabilisation, binding, purification, scavenging and immobilisation of bio-polymers.

- Any industry based on protein expression, protein technology, medicine, or specialty
- 15 plastics and glasses could realise profit following implementation of this process.

Applicants are also exploring secondary applications that might exploit the physico-chemical properties of this system.

REFERENCES

- Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol. 135 (K. Mosbach, Ed) Academic Press, 1987, NY,
- Methods in Enzymology: Immobilised Enzymes and Cells, Part B, Vol.137 (K. Mosbach, Ed) Academic Press, 1988, NY;
- Immobilisation of enzymes and cells (GF Bickerstaff, Ed.) Humana Press, 1997, NJ, USA,
- Immobilised biomolecules in analysis: A practical approach (T Cass and FS Ligler, Eds) Oxford University Press, 1998, NY.
- S. Nock, J.A Spudich and P. Wagner (1997) "Reversible, site-specific immobilisation of polyarginine-tagged fusion proteins on mica surfaces" FEBS Letters 141, 233-238)
- B Jonsson, B Lindman, k. Holmberg and B Kronberg, Interaction of Polymers with Surfaces: in surfactant and polymers in aqueous solution, John Wiley and Sons, 1998, NY.
- G.P. Royer (1974) Supports for immobilized enzymes, CHEMTECH 4, 699
- Y Harada, K Yasuda, S Nomura, n Kajimura and Y C Sasaki (1998) Vectorially Oriented Fixation of Membrane-Embedded Bacteriorhodopsin onto an Inert Base" Langmuir 14, 1829-1835.
- Inouye, S et al. "Aequorea green fluorescent protein: Expression of the gene and fluorescence characteristics of the recombinant protein" FEBS Letters 341 (1994) pages 227-280.
- Dyke, Michael W. Van; Sirito, Maro and Sawadogo, Michèle "Single-step purification of bacterially expressed polypeptides containing an oligo-histidine domain", Gene, Col.111, Issue 1, 1 Feb. 1992, pages 99-104.
- Green fluorescent protein: properties, applications and protocols (m Chalfie, S kain, Eds.) Wiley-Liss, 1998, NY;
- Protein localisation by fluorescence microscopy: a practical approach (VJ Allan, Ed.) Oxford University Press, 2000, NY; Imprint oxford; New York: Oxford University Press, c2000; Oancea, Diacylglycerol Signalling in Living Cells "The Journal of Cell Biology, Volume 140, No.3,
- E et al "Green Fluorescent Protein (GFP)-tagged Cysteine-rich Domains from protein Kinase Cas Fluorescent Indications for February 9, 1998, pages 485-498.
- J Sambrook and D W Russel, Molecular cloning: a laboratory manual Vol 1-3, Cold Spring Harbor Laboratory Press, 2001, Cold Spring Harbor.

PROTOCOL 1**Plasmid or Cosmid DNA Purification Using****QIAGEN® Plasmid Midi and Maxi Kits****Things to do before starting**

- 5 • Add the provided RNase A solution to Buffer P1 before use. Use one vial of RNase A (spin down briefly before use) per bottle of Buffer P1, to give a final concentration of 100 µg/ml.
- Check Buffer P2 for SDS precipitation due to low storage temperatures. If necessary, dissolve the SDS by warming to 37°C.
- 10 • Pre-chill Buffer P3 to 4°C.

Procedure

1. Pick a single colony from a freshly streaked selective plate and inoculate a starter culture of 2–5 ml LB medium containing the appropriate selective antibiotic. Incubate for ~8 h at 37°C with vigorous shaking (~300 rpm).
- 15 2. Dilute the starter culture 1/500 to 1/1000 into selective LB medium. For high-copy plasmids inoculate 25 ml medium. For low-copy plasmids, inoculate 100 ml medium. Grow at 37°C for 12–16 h with vigorous shaking (~300 rpm).
3. Harvest the bacterial cells by centrifugation at 6000 x *g* for 15 min at 4°C.
4. Resuspend the bacterial pellet in 4 ml of Buffer P1.
- 20 5. Add 4 ml of Buffer P2, mix gently but thoroughly by inverting 4–6 times, and incubate at room temperature for 5 min. Do not vortex, as this will result in shearing of genomic DNA. The lysate should appear viscous. Do not allow the lysis reaction to proceed for more than 5 min. After use, the bottle containing Buffer P2 should be closed immediately to avoid acidification from CO₂ in the air.
- 25 6. Add 4 ml of chilled Buffer P3, mix immediately but gently by inverting 4–6 times, and incubate on ice for 15 min or 20 min.
7. Centrifuge at 20,000 x *g* for 30 min at 4°C. Remove supernatant containing plasmid DNA promptly. After centrifugation the supernatant should be clear.
8. Centrifuge the supernatant again at 20,000 x *g* for 15 min at 4°C. Remove supernatant
- 30 containing plasmid DNA promptly.
9. Equilibrate a QIAGEN-tip 100 by applying 4 ml Buffer QBT, and allow the column to empty by gravity flow. Allow the QIAGEN-tip to drain completely.
10. Apply the supernatant from step 8 to the QIAGEN-tip and allow it to enter the resin by gravity flow.

11. Wash the QIAGEN-tip with 2 x 10 ml Buffer QC. Allow Buffer QC to move through the QIAGEN-tip by gravity flow.

12. Elute DNA with 5 ml Buffer QF. Collect the eluate in a 10 ml or 30 ml tube. Use of polycarbonate centrifuge tubes is not recommended as polycarbonate is not resistant to the alcohol used in subsequent steps. If you wish to stop the protocol and continue later, store the eluate at 4°C. Storage periods longer than overnight are not recommended.

13. Precipitate DNA by adding 3.5 ml room-temperature isopropanol to the eluted DNA. Mix and centrifuge immediately at 15,000 x g for 30 min at 4°C. Carefully decant the supernatant. All solutions should be at room temperature in order to minimize salt precipitation, although centrifugation is carried out at 4°C to prevent overheating of the sample. Isopropanol pellets have a glassy appearance and may be more difficult to see than the fluffy, salt-containing pellets that result from ethanol precipitation. Marking the outside of the tube before centrifugation allows the pellet to be more easily located. Isopropanol pellets are also more loosely attached to the side of the tube, and care should be taken when removing the supernatant.

14. Wash DNA pellet with 2 ml of room-temperature 70% ethanol, and centrifuge at 15,000 x g for 10 min. Carefully decant the supernatant without disturbing the pellet. The 70% ethanol removes precipitated salt and replaces isopropanol with the more volatile ethanol, making the DNA easier to redissolve.

15. Air-dry the pellet for 5–10 min, and redissolve the DNA in a suitable volume of buffer (e.g., TE buffer, pH 8.0, or 10 mM Tris·Cl, pH 8.5). Redissolve the DNA pellet by rinsing the walls to recover all the DNA, especially if glass tubes have been used. Pipetting the DNA up and down to promote resuspension may cause shearing and should be avoided. Overdrying the pellet will make the DNA difficult to redissolve. DNA dissolves best under slightly alkaline conditions; it does not easily dissolve in acidic buffers.

Determination of yield: To determine the yield, DNA concentration should be determined by both UV spectrophotometry and quantitative analysis on an agarose gel.

PROTOCOL 2

QIAquick Gel Extraction Kit Protocol using a microcentrifuge

This protocol is designed to extract and purify DNA of 70 bp to 10 kb from standard or low-melt agarose gels in TAE or TBE buffer. Up to 400 mg agarose can be processed per spin column.

Notes: The yellow color of Buffer QG indicates a pH ~7.5.

- 5 • Add ethanol (96–100%) to Buffer PE before use (see bottle label for volume).
- Isopropanol (100%) and a heating block or water bath at 50°C are required.
- All centrifugation steps are carried out at 13,000 rpm (~17,900 x g) in a conventional table-top microcentrifuge.
- 3 M sodium acetate, pH 5.0, may be necessary.
- 10 1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel. Minimize the size of the gel slice by removing extra agarose.
2. Weigh the gel slice in a colorless tube. Add 3 volumes of Buffer QG to 1 volume of gel (100 mg ~ 100 µl). The maximum amount of gel slice per QIAquick column is 400 mg; for gel slices >400 mg use more than one QIAquick column.
- 15 3. Incubate at 50°C for 10 min (or until the gel slice has completely dissolved). To help dissolve gel, mix by vortexing the tube every 2–3 min during the incubation. IMPORTANT: Solubilize agarose completely.
4. After the gel slice has dissolved completely, check that the color of the mixture is yellow (similar to Buffer QG without dissolved agarose). If the color of the mixture is orange or
- 20 violet, add 10 µl of 3 M sodium acetate, pH 5.0, and mix. The color of the mixture will turn to yellow. The adsorption of DNA to the QIAquick membrane is efficient only at pH ~7.5. Buffer QG contains a pH indicator which is yellow at pH ~7.5 and orange or violet at higher pH, allowing easy determination of the optimal pH for DNA binding.
5. Add 1 gel volume of isopropanol to the sample and mix. This step increases the yield of
- 25 DNA fragments <500 bp and >4 kb. For DNA fragments between 500 bp and 4 kb, addition of isopropanol has no effect on yield. Do not centrifuge the sample at this stage.
6. Place a QIAquick spin column in a provided 2 ml collection tube.
7. To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1 min. The maximum volume of the column reservoir is 800 µl. For sample volumes of more
- 30 than 800 µl, simply load and spin again.
8. Discard flow-through and place QIAquick column back in the same collection tube. Collection tubes are re-used to reduce plastic waste.

9. (Optional): Add 0.5 ml of Buffer QG to QIAquick column and centrifuge for 1 min. This step will remove all traces of agarose. It is only required when the DNA will subsequently be used for direct sequencing, in vitro transcription or microinjection.
10. To wash, add 0.75 ml of Buffer PE to QIAquick column and centrifuge for 1 min. Note: If
5 the DNA will be used for salt sensitive applications, such as blunt-end ligation and direct sequencing, let the column stand 2–5 min after addition of Buffer PE, before centrifuging.
11. Discard the flow-through and centrifuge the QIAquick column for an additional 1 min at 13,000 rpm (~17,900 x g). IMPORTANT: Residual ethanol from Buffer PE will not be completely removed unless the flow-through is discarded before this additional
10 centrifugation.
12. Place QIAquick column into a clean 1.5 ml microcentrifuge tube.
13. To elute DNA, add 50 µl of Buffer EB (10 mM Tris·Cl, pH 8.5) or H₂O to the center of the QIAquick membrane and centrifuge the column for 1 min. Alternatively, for increased DNA concentration, add 30 µl elution buffer to the center of the QIAquick membrane, let the
15 column stand for 1 min, and then centrifuge for 1 min.
- IMPORTANT: Ensure that the elution buffer is dispensed directly onto the QIAquick membrane for complete elution of bound DNA. The average eluate volume is 48 µl from 50 µl elution buffer volume, and 28 µl from 30 µl.
- Elution efficiency is dependent on pH. The maximum elution efficiency is achieved between
20 pH 7.0 and 8.5. When using water, make sure that the pH value is within this range, and store DNA at –20°C as DNA may degrade in the absence of a buffering agent. The purified DNA can also be eluted in TE (10 mM Tris·Cl, 1 mM EDTA, pH 8.0), but the EDTA may inhibit subsequent enzymatic reactions.

PROTOCOL 3**QIAprep Spin Miniprep Kit Protocol using a microcentrifuge**

This protocol is designed for purification of up to 20 µg of high-copy plasmid DNA from 1–5 ml overnight cultures of *E. coli* in LB (Luria-Bertani) medium.

- 5 All protocol steps should be carried out at room temperature.

Procedure

1. Resuspend pelleted bacterial cells in 250 µl Buffer P1 and transfer to a microcentrifuge tube. Ensure that RNase A has been added to Buffer P1. No cell clumps should be visible after resuspension of the pellet.
- 10 2. Add 250 µl Buffer P2 and gently invert the tube 4–6 times to mix. Do not vortex, as this will result in shearing of genomic DNA. Do not allow the lysis reaction to proceed for more than 5 min.
3. Add 350 µl Buffer N3 and invert the tube immediately but gently 4–6 times. To avoid localized precipitation, mix the solution gently but thoroughly, immediately after addition of
- 15 Buffer N3. The solution should become cloudy.
4. Centrifuge for 10 min at maximum speed in a tabletop microcentrifuge.
5. Apply the supernatants from step 4 to the QIAprep column by decanting or pipetting.
6. Centrifuge for 30–60 s. Discard the flow-through.
7. (Optional): Wash the QIAprep spin column by adding 0.5 ml Buffer PB and centrifuging
- 20 for 30–60 s. Discard the flow-through. This step is necessary to remove trace nuclease activity when using *endA*⁺ strains such as the JM series, HB101 and its derivatives, or any wild-type strain, which have high levels of nuclease activity or high carbohydrate content.
8. Wash QIAprep spin column by adding 0.75 ml Buffer PE and centrifuging for 30–60 seconds.
- 25 9. Discard the flow-through, and centrifuge for an additional 1 min to remove residual wash buffer. IMPORTANT: Residual wash buffer will not be completely removed unless the flow-through is discarded before this additional centrifugation. Residual ethanol from Buffer PE may inhibit subsequent enzymatic reactions.
10. Place the QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute DNA, add 50
- 30 µl Buffer EB (10 mM Tris·Cl, pH 8.5) or water to the center of each QIAprep column, let stand for 1 min, and centrifuge for 1 min.

PROTOCOL 4**ProBond Purification System****A manual of methods for purification of
polyhistidine-containing recombinant proteins**

ProBond resin should be stored at +4°C. All other components of the protocol may be stored at room temperature.

Additional Materials: All native purification buffers are prepared from the 5X Native Purification Buffer (250 mM Na₃PO₄; 2.5 M NaCl) and the 3 M Imidazole.

- 5 Resin and Column Specifications: ProBond resin is precharged with Ni²⁺ ions and appears blue in color. It is provided as a 50% slurry in 20% ethanol. Binding capacity of ProBond resin: 1.5 mg of protein per ml of resin, Recommended flow rate: 0.5 ml/min. pH stability (long term): 3.13, pH stability (short term): 2.14

- 10 Binding Characteristics: ProBond resin uses the chelating ligand iminodiacetic acid (IDA) in a highly cross-linked agarose matrix. IDA binds Ni²⁺ ions by three coordination sites.

Preparation of Native Purification Buffers

You must dilute and adjust the pH of the 5X Native Purification Buffer to create 1X Native Purification Buffer (50 mM Na₃PO₄; 500 mM NaCl; pH 8.0). From this, you can create the following buffers: Native Binding Buffer, Native Wash Buffer, Native Elution Buffer.

- 15 To prepare the native buffers, you will need the following reagents:
5X Native Purification Buffer, 3M Imidazole, NaOH, HCl, Sterile distilled water.

- 20 Imidazole Concentration in Native Buffers: Imidazole is included in the native wash and elution buffers to minimize the binding of untagged, contaminating proteins and increase the purity of the target protein with fewer wash steps. Note that, if your level of contaminating proteins is high, imidazole can also be added to the native binding buffer. If your protein does not bind well under these conditions, you can experiment with lowering or eliminating the concentration of imidazole in the buffers and increasing the number of wash and elution steps.

- 25 1X Native Purification Buffer: For the following recipes, you must dilute and adjust the pH of the 5X Native Purification Buffer (supplied in the kit) to create 1X Native Purification Buffer. To prepare 100 ml of 1X Native Purification Buffer, combine: 80 ml of H₂O, 20 ml of 5X Native Purification Buffer. Adjust pH to 8.0 with NaOH or HCl

Native Binding Buffer Without Imidazole: Reserve 30 ml of the 1X Native Purification Buffer for use as the Native Binding Buffer (for column preparation, cell lysis, and binding).

Native Wash Buffer: To prepare 50 ml of Native Wash Buffer with 20 mM imidazole, combine; 50 ml of 1X Native Purification Buffer, 335 µl of 3M Imidazole. Adjust pH to 8.0 with NaOH or HCl.

5 Native Elution Buffer: To prepare 15 ml of Native Elution Buffer with 250 mM imidazole, combine: 13.75 ml of 1X Native Purification Buffer, 1.25 ml of 3M Imidazole. Adjust pH to 8.0 with NaOH or HCl.

10 Preparation of the ProBond Columns: Do not use strong reducing agents such as DTT with ProBond[®] columns. DTT reduces the nickel ions in the resin. In addition, do not use strong chelating agents such as EDTA or EGTA in the loading buffers or wash buffers, as these will strip the nickel from the columns. Be sure to check the pH of your buffers before starting

Column Preparation: When preparing a column as described below, make sure that the snap-off cap at the bottom of the column remains intact. To prepare a column:

- 15 1. Resuspend the ProBond[®] resin in its bottle by inverting and gently tapping the bottle repeatedly.
- 20 2. Pipet or pour 2 ml of the resin into a 10-ml Purification Column (Scale up the resin amount if necessary, considering the binding capacity of ProBond resin. All following steps are written for 2mL resin volume). Gently pellet it by low-speed centrifugation (1 minute at 800 x g). Gently aspirate the supernatant. Add 6 ml of sterile, distilled water and resuspend the resin by alternately inverting and gently tapping the column. Pipet or pour 2 ml of the resin into a 10-ml Purification Column. Gently pellet it by low-speed centrifugation (1 minute at 800 x g). Gently aspirate the supernatant.
- 25 3. Add 6 ml of sterile, distilled water and resuspend the resin by alternately inverting and gently tapping the column.
- 30 4. Repellet the resin using centrifugation as described in Step 2, and gently aspirate the supernatant.
5. For purification under Native Conditions, add 6 ml of Native Binding Buffer (see the recipe on previous page).
6. Resuspend the resin by alternately inverting and gently tapping the column.
7. Repellet the resin using centrifugation as described in Step 2, and gently aspirate the supernatant.
8. Repeat Steps 5 through 7.

Storing Prepared Columns: To store a column containing resin, add or 20% ethanol as a preservative and cap or parafilm the column. Store at room temperature.

Preparation of Bacteria Cell Lysate in Native Conditions

5 Follow the procedure below to prepare bacteria cell lysate under native conditions. Scale up or down as necessary.

1. Harvest cells from a 50 ml culture by centrifugation (e.g., 5000 rpm for 5 minutes in a Sorvall SS-34 rotor). Resuspend the cells in 8 ml of Native Binding Buffer.
2. Add 8 mg of lysozyme and incubate on ice for 30 minutes.
3. Using a sonicator equipped with a microtip, sonicate the solution on ice using six 10-second bursts at high intensity with a 10-second cooling period between each burst.
- 10 4. Centrifuge the lysate at 3,000 x g for 15 min to pellet the cellular debris. Transfer the supernatant to a fresh tube.
5. Store the lysate on ice or freeze at -20° C. Save 20 µl of the lysate at +4° C for SDS-PAGE analysis

15 Introduction

In the following procedure, use the prepared Native Wash Buffer and Native Elution Buffer and the columns and cell lysate prepared under native conditions. Be sure to check the pH of your buffers before starting.

Purification Under Native Conditions

- 20 Using the native buffers, columns and cell lysate, follow the procedure below to purify proteins under native conditions (remember to scale up if necessary):
1. Add 8 ml of lysate to a prepared Purification Column.
 2. Bind for 30-60 minutes using gentle agitation to keep the resin suspended in the lysate solution.
 - 25 3. Settle the resin by low speed centrifugation (800 x g), and carefully aspirate the supernatant. Save supernatant at +4° C for SDS-PAGE analysis.
 4. Wash with 8 ml Native Wash Buffer. Settle the resin by gravity or low speed centrifugation (800 x g), and carefully aspirate the supernatant. Save supernatant at +4° C for SDS-PAGE analysis.
 - 30 5. Repeat Step 4 three more times.
 6. Clamp the column in a vertical position and snap off the cap on the lower end. Elute the protein with 8-12 ml Native Elution Buffer. Collect 0.5 or 1 ml fractions and analyze with SDS-PAGE.

6. Clamp the column in a vertical position and snap off the cap on the lower end. Elute the protein with 8-12 ml Native Elution Buffer. Collect 0.5 or 1 ml fractions and analyze with SDS-PAGE.

- 5 **Note:** Elution fractions should be stored at +4° C. If -20° C storage is required, glycerol should be added to the fraction. For long term storage, protease inhibitors can be added.

Recharging ProBond. Resin

ProBond[®] resin can be used for up to three or four purifications of the same protein without recharging. We recommend not recharging the resin more than three times and only reusing it for purification of the same recombinant protein.

- 10 To recharge 2 ml of resin in a purification column:
1. Wash the column two times with 8 ml of 50 mM EDTA to strip away the chelated nickel ions.
 2. Wash the column two times with 8 ml of 0.5M NaOH.
 3. Wash the column two times with 8 ml of sterile, distilled water.
 - 15 4. Recharge the column with two washes of 8 ml NiCl₂ hexahydrate at a concentration of 5 mg/ml prepared in sterile, distilled water.
 5. Wash the column two times with 8 ml of distilled water.
 6. Add 20% ethanol as a preservative and cap or parafilm the column. Store at room temperature.

WO 2004/083439

PCT/TR2003/000019
10/550226SEQUENCE LISTING 1

```

1  GGTACCGGTA  GAAAAAATGA  GTAAAGGAGA  AGAACTTTTC  ACTGGAGTTG
51  TCCCAATTCT  TGTGAATTA  GATGGTGATG  TTAATGGGCA  CAAATTTTCT
101  GTCAGTGGAG  AGGGTGAAGG  TGATGCAACA  TACGGAAAAC  TTACCCTTAA
5  151  ATTTATTTGC  ACTACTGGAA  AACTACCTGT  TCCATGGCCA  ACACTTGTCa
201  CTACTTTCTC  TTATGGTGTT  CAATGCTTTT  CCCGTTATCC  GGATCATATG
251  AAACGGCATG  ACTTTTCAA  GAGTGCCATG  CCCGAAGGTT  ATGTACAGGA
301  ACGCACTATA  TCTTCAAAG  ATGACGGGAA  CTACAAGACG  CGTGCTGAAG
351  TCAAGTTTGA  AGGTGATACC  CTTGTTAATC  GTATCGAGTT  AAAAGGTATT
10  401  GATTTTAAAG  AAGATGGAAA  CATTCTCGGA  CACAACTCG  AGTACAATA
451  TAACTCACAC  AATGTATACA  TCACGGCAGA  CAAACAAAAG  AATGGAATCA
501  AAGCTAACTT  CAAAATTCGC  CACAACATG  AAGATGGATC  CGTTCAACTA
551  GCAGACCATT  ATCAACAAA  TACTCCAATT  GCGATGGCC  CTGTCCTTTT
601  ACCAGACAAC  CATTACCTGT  CGACACAATC  TGCCCTTCG  AAAGATCCCA
15  651  ACGAAAAGCG  TGACCACATG  GTCCTTCTTG  AGTTTGTAAC  TGCTGCTGGG
701  ATTACACATG  GCATGGATGA  GCTCTACAAA  TAA

```

SEQUENCE LISTING 2

	1	CATCACCATC	ACCATCACCC	CATGAGCGAT	TACGACATCC	CCACTACTGA
	51	GAATCTTTAT	TTTCAGGGCG	CCATGGCGGC	GGCGGTTCTGG	ATGAACATCC
	101	AGATGCTGCT	GGAGGCGGCC	GACTATCTGG	AGCGGCGGGA	GAGAGAAGCT
5	151	GAACATGGTT	ATGCCTCCAT	GTTACCATAC	AAAAACAAGG	ACAGAGATGC
	201	CTTAAACGG	AGGAACAAAT	CCAAAAAGAA	TAACAGCAGT	AGCAGATCAA
	251	CTCACAATGA	AATGGAGAAG	AATAGACGGG	CTCATCTTCG	CTTGTGCTTG
	301	GAGAAGTTGA	AGGGGCTGGT	GCCACTGGGA	CCCGAATCAA	GTCGACACAC
	351	TACGTTGAGT	TTATTAACAA	AAGCCAAATT	GCACATAAAG	AAACTTGAAG
10	401	ATTGTGACAG	AAAAGCCGTT	CACCAAATCG	ACCAGCTTCA	GCGAGAGCAG
	451	CGACACCTGA	AGAGGCAGCT	GGAGAAGCTG	GGCATTGAGA	GGATCCGGAT
	501	GGACAGCATC	GGCTCCACCG	TCTCCTCGGA	GCGCTCCGAC	TCCGACAGGG
	551	AAGAAATCGA	CGTTGACGTG	GAGAGCACGG	ACTATCTCAC	AGGTGATCTG
	601	GACTGGAGCA	GCAGCAGTGT	GAGCGACTCT	GACGAGCGGG	GCAGCATGCA
15	651	GAGCCTCGGC	AGTGATGAGG	GCTATTCCAG	CACCAGCATC	AAGAGAATAA
	701	AGCTGCAGGA	CAGTCACAAG	GCGTGTCTTG	GTCTCTAACT	AGTGGTACCG
	751	GATCCGAATT	CGAGCTCCGT	CGACAAGCTT	GCGGCCGCAC	TCGAGCACC
	801	CCACCACCAC	CACTGAGATC	CGGCTGCTAA	CAAAGCCCGA	AAGGAAGCTG
	851	AGTTGGCTGC	TGCCACCGCT	GAGCAATAAC	TAGCATAACC	CCTTGGGGCC
20	901	TCTAAACGGG	TCTTGAGGGG	TTTTTTGCTG	AAAGGAGGAA	CTATATCCGG
	951	ATTGGCGAAT	GGGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT
	1001	GGTGGTTACG	CGCAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCCCGCG
	1051	CTCCTTTTCG	TTTCTTCCCT	TCCTTTCTCG	CCACGTTTCG	CGGCTTTCCC
	1101	CGTCAAGCTC	TAAATCGGGG	GCTCCCTTTA	GGGTTCCGAT	TTAGTGCTTT
25	1151	ACGGCACCTC	GACCCCAAAA	AACTTGATTA	GGGTGATGGT	TCACGTAGTG
	1201	GGCCATCGCC	CTGATAGACG	GTTTTTCGCC	CTTTGACGTT	GGAGTCCACG
	1251	TTCTTTAATA	GTGGACTCTT	GTTCCAAACT	GGAACAACAC	TCAACCTAT
	1301	CTCGGTCTAT	TCTTTTGATT	TATAAGGGAT	TTTGCCGATT	TCGGCCTATT
	1351	GGTTAAAAAA	TGAGCTGATT	TAACAAAAAT	TTAACGCGAA	TTTTAACAAA
30	1401	ATATTAACGT	TTACAATTTT	AGGTGGCACT	TTTCGGGGAA	ATGTGCGCGG
	1451	AACCCCTATT	TGTTTATTTT	TCTAAATACA	TTCAAATATG	TATCCGCTCA
	1501	TGAATTAATT	CTAGAAAAA	CTCATCGAGC	ATCAAATGAA	ACTGCAATTT
	1551	ATTCATATCA	GGATTATCAA	TACCATATTT	TTGAAAAAGC	CGTTTCTGTA
	1601	ATGAAGGAGA	AAACTCACCG	AGGCAGTTCC	ATAGGATGGC	AAGATCCTGG
35	1651	TATCGGTCTG	CGATTCCGAC	TCGTCCAACA	TCAATACAAC	CTATTATTTT
	1701	CCCCTCGTCA	AAAATAAGGT	TATCAAGTGA	GAAATCACCA	TGAGTGACGA
	1751	CTGAATCCGG	TGAGAATGGC	AAAAGTTTAT	GCATTTCTTT	CCAGACTTGT
	1801	TCAACAGGCC	AGCCATTACG	CTCGTCATCA	AAATCACTCG	CATCAACCAA
	1851	ACCGTTATTC	ATTCTGTGAT	GCGCCTGAGC	GAGACGAAAT	ACGCGATCGC
40	1901	TGTTAAAAGG	ACAATTACAA	ACAGGAATCG	AATGCAACCG	GCGCAGGAAC
	1951	ACTGCCAGCG	CATCAACAAT	ATTTTCACCT	GAATCAGGAT	ATTCTTCTAA
	2001	TACCTGGAAT	GCTGTTTTCC	CGGGGATCGC	AGTGGTGAGT	AACCATGCAT
	2051	CATCAGGAGT	ACGGATAAAA	TGCTTGATGG	TCGGAAGAGG	CATAAATTCC
	2101	GTCAGCCAGT	TTAGTCTGAC	CATCTCATCT	GTAACATCAT	TGGCAACGCT
45	2151	ACCTTTGCCA	TGTTTCAGAA	ACAACTCTGG	CGCATCGGGC	TTCCCATACA
	2201	ATCGATAGAT	TGTCGCACCT	GATTGCCCGA	CATTATCGCG	AGCCCATTTA
	2251	TACCCATATA	AATCAGCATC	CATGTTGGAA	TTTAATCGCG	GCCTAGAGCA
	2301	AGACGTTTCC	CGTTGAATAT	GGCTCATAAC	ACCCCTTGTA	TTACTGTTTA
	2351	TGTAAGCAGA	CAGTTTTATT	GTTTCATGACC	AAAATCCCTT	AACGTGAGTT
50	2401	TTGCTTCCAC	TGAGCGTCAG	ACCCCGTAGA	AAAGATCAAA	GGATCTTCTT
	2451	GAGATCCTTT	TTTTCTGCGC	GTAATCTGCT	GCTTGCAAAC	AAAAAAACCA
	2501	CCGCTACACG	CGGTGGTTTG	TTTGCCGGAT	CAAGAGCTAC	CAACTCTTTT
	2551	TCCGAAGGTA	ACTGGCTTCA	GCAGAGCGCA	GATACCAAAT	ACTGTCCTTC
	2601	TAGTGTAGCC	GTAAGTAGGC	CACCACTTCA	AGAACTCTGT	AGCACCGCCT
55	2651	ACATACCTCG	CTCTGCTAAT	CCTGTTACCA	GTGGCTGCTG	CCAGTGCGCA
	2701	TAAGTCGTGT	CTTACCGGGT	TGGACTCAAG	ACGATAGTTA	CCGGATAAAG
	2751	CGCAGCGGTC	GGGCTGAACG	GGGGGTTCTG	GCACACAGCC	CAGCTTGGAG
	2801	CGAACGACCT	ACACCGAACT	GAGATACCTA	CAGCGTGAGC	TATGAGAAAG
	2851	CGCCACGCTT	CCCGAAGGGA	GAAAGGCGGA	CAGGTATCCG	GTAAGCGGCA
60	2901	GGGTGCGAAC	AGGAGAGCGC	ACGAGGGAGC	TTCCAGGGGG	AAACGCCTGG
	2951	TATCTTTATA	GTCCTGTCTG	GTTTCGCCAC	CTCTGACTTG	AGCGTCGATT

	3001	TTTGTGATGC	TCGTCAGGGG	GGCGGAGCCT	ATGGAAAAAC	GCCAGCAACG
	3051	CGGCCTTTT	ACGGTTCTTG	GCCTTTTGCT	GGCCTTTTGC	TCACATGTTT
	3101	TTTCCTGCGT	TATCCCTGTA	TTCTGTGGAT	AACCGTATTA	CCGCCTTTGA
	3151	GTGAGCTGAT	ACCGCTCGCC	GCAGCCGAAC	GACCGAGCGC	AGCGAGTCAG
5	3201	TGAGCGAGGA	AGCGGAAGAG	CGCCTGATGC	GGTATTTTCT	CCTTACGCAT
	3251	CTGTGCGGTA	TTTCACACCG	CATATATGGT	GCACTCTCAG	TACAATCTGC
	3301	TCTGATGCCG	CATAGTTAAG	CCAGTATACA	CTCCGCTATC	GCTACGTGAC
	3351	TGGGTCATGG	CTGCGCCCCG	ACACCCGCCA	ACACCCGCTG	ACGCGCCCTG
	3401	ACGGGCTTGT	CTGCTCCCGG	CATCCGCTTA	CAGACAAGCT	GTGACCGTCT
10	3451	CCGGGAGCTG	CATGTGTGAG	AGGTTTTCAC	CGTCATCACC	GAAACGCGCG
	3501	AGGCAGCTGC	GGTAAAGCTC	ATCAGCGTGG	TCGTGAAGCG	ATTACACAGAT
	3551	GTCTGCCTGT	TCATCCGCGT	CCAGCTCGTT	GAGTTTCTCC	AGAAGCGTTA
	3601	ATGTCTGGCT	TCTGATAAAG	CGGGCCATGT	TAAGGGCGGT	TTTTCTCTGT
	3651	TTGGTCACTG	ATGCCTCCGT	GTAAGGGGGA	TTTCTGTTCA	TGGGGGTAAT
15	3701	GATACCGATG	AAACGAGAGA	GGATGCTCAC	GATACGGGTT	ACTGATGATG
	3751	AACATGCCCG	GTTACTGGAA	CGTTGTGAGG	GTAACAACCT	GGCGGTATGG
	3801	ATGCGGCGGG	ACCAGAGAAA	AATCACTCAG	GGTCAATGCC	AGCGCTTCGT
	3851	TAATACAGAT	GTAGGTGTTT	CACAGGGTAG	CCAGCAGCAT	CCTGCGATGC
	3901	AGATCCGGAA	CATAATGGTG	CAGGGCGCTG	ACTTCCGCGT	TTCCAGACTT
20	3951	TACGAAACAC	GGAAACCGAA	GACCATTTCAT	GTGTTGCTC	AGGTGCGAGA
	4001	CGTTTTGTCAG	CAGCAGTCGC	TTTACGTTTC	CTCGCGTATC	GGTGATTCAT
	4051	TCTGCTAACC	AGTAAGGCAA	CCCCGCCAGC	CTAGCCGGGT	CCTCAACGAC
	4101	AGGAGCACGA	TCATGCGCAC	CCGTGGGGCC	GCCATGCCGG	CGATAATGGC
	4151	CTGCTTCTCG	CCGAAACGTT	TGGTGGCGGG	ACCAGTGACG	AAGGCTTGAG
25	4201	CGAGGGCGTG	CAAGATTCCG	AATACCGCAA	GCGACAGGCC	GATCATCGTC
	4251	GCGCTCCAGC	GAAAGCGGTC	CTCGCCGAAA	ATGACCCAGA	GCGCTGCCGG
	4301	CACCTGTCTT	ACGAGTTGCA	TGATAAAGAA	GACAGTCATA	AGTGCGGCGA
	4351	CGATAGTCAT	GCCCCGCGCC	CACCGGAAGG	AGCTGACTGG	GTGAAGGCT
	4401	CTCAAGGGCA	TCGGTTCGAG	TCCCGGTGCC	TAATGAGTGA	GCTAACTTAC
30	4451	ATTAATTGCG	TTGCGCTCAC	TGCCCGCTTT	CCAGTCGGGA	AACCTGTCTG
	4501	GCCAGCTGCA	TTAATGAATC	GGCCAACGCG	CGGGGAGAGG	CGGTTTGCGT
	4551	ATTGGGCGCC	AGGGTGGTTT	TTCTTTTCAC	CAGTGAGACG	GGCAACAGCT
	4601	GATTGCCCTT	CACCGCTTGG	CCCTGAGAGA	GTGTCAGCAA	GCGGTCCACG
	4651	CTGGTTTGCC	CCAGCAGGCG	AAAATCCTGT	TTGATGGTGG	TTAACGGCGG
35	4701	GATATAACAT	GAGCTGTCTT	CGGTATCGTC	GTATCCCACT	ACCGAGATAT
	4751	CCGCACCAAC	GCGCAGCCCG	GACTCGGTAA	TGGCGCGCAT	TGCGCCGACG
	4801	GCCATCTGAT	CGTTGGCAAC	CAGCATCGCA	GTGGGAACGA	TGCCCTCATT
	4851	CAGCATTGTC	ATGGTTTGTT	GAAAACCGGA	CATGGCACTC	CAGTCCGCTT
	4901	CCCGTTCCGC	TATCGGCTGA	ATTTGATTGC	GAGTGAGATA	TTTATGCCAG
40	4951	CCAGCCAGAC	GCAGACGCGC	CGAGACAGAA	CTTAATGGGC	CCGCTAACAG
	5001	CGCGATTTGC	TGGTGACCCA	ATGCGACCAG	ATGCTCCACG	CCCAGTCGCG
	5051	TACCGTCTTC	ATGGGAGAAA	ATAATACTGT	TGATGGGTGT	CTGGTCAGAG
	5101	ACATCAAGAA	ATAACGCCGG	AACATTAGTG	CAGGCAGCTT	CCACAGCAAT
	5151	GGCATCCTGG	TCATCCAGCG	GATAGTTAAT	GATCAGCCCA	CTGACGCGTT
45	5201	GCGCGAGAAG	ATTGTGCACC	GCCGCTTTAC	AGGCTTCGAC	GCCGCTTCGT
	5251	TCTACCATCG	ACACCACCAC	GCTGGCACCC	AGTTGATCGG	CGCGAGATTT
	5301	AATCGCCGCG	ACAATTTGCG	ACGGCGCGTG	CAGGGCCAGA	CTGGAGGTGG
	5351	CAACGCCAAT	CAGCAACGAC	TGTTTGCCCG	CCAGTTGTTG	TGCCACGCGG
	5401	TTGGGAATGT	AATTCAGCTC	CGCCATCGCC	GCTTCCACTT	TTTCCCGCGT
50	5451	TTTCGCAGAA	ACGTGGCTGG	CCTGGTTCAC	CACGCGGGAA	ACGGTCTGAT
	5501	AAGAGACACC	GGCATACTCT	GCGACATCGT	ATAACGTTAC	TGGTTTCACA
	5551	TTACCAACCC	TGAATTGACT	CTCTTCCGGG	CGCTATCATG	CCATACCGCG
	5601	AAAGGTTTTG	CGCCATTTCG	TGGTGTCCGG	GATCTCGACG	CTCTCCCTTA
	5651	TGCGACTCCT	GCATTAGGAA	GCAGCCCACT	AGTAGGTTGA	GGCCGTTGAG
55	5701	CACCGCCGCC	GCAAGGAATG	GTGCATGCAA	GGAGATGGCG	CCCACAGTCT
	5751	CCCCGGCCAC	GGGGCCTGCC	ACCATAACCA	CGCCGAAACA	AGCGCTCATG
	5801	AGCCCCAAGT	GGCGAGCCCG	ATCTTCCCCA	TCGGTGATGT	CGGCGATATA
	5851	GGCGCCAGCA	ACCGACCTTG	TGGCGCCGGT	GATGCCGGCC	ACGATGCGTC
	5901	CGGCGTAGAG	GATCGAGATC	TCGATCCCGC	GAAATTAATA	CGACTCACTA
60	5951	TAGGGGAATT	GTGAGCGGAT	AACAATTCCC	CTCTAGAAAT	AATTTTGATT
	6001	TAACTTTAAG	AAGGAGATAT	ACCATGAAA		

SEQUENCE LISTING 3

```

1  CATCACCATC ACCATCACCC CATGAGCGAT TACGACATCC CCACTACTGA
51 GAATCTTTAT TTTCAGGGCG CCATGGGAGG CACGGTACCG GATCCGAATT
101 CGAGCTCCGT CGACAAGCTT GCGGCCGCAC TCGAGACCCA CCACCACCAC
5  151 CACTGAGATC CGGCTGCTAA CAAAGCCCGA AAGGAAGCTG AGTTGGCTGC
201 TGCCACCGCT GAGCAATAAC TAGCATAACC CCTTGGGGCC TCTAAACGGG
251 TCTTGAGGGG TTTTTTGCTG AAAGGAGGAA CTATATCCGG ATTGGCGAAT
301 GGGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG
351 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC
10  401 TTTCTTCCCT TCCTTCTCTG CCACGTTTCG CGGCTTTCCT CGTCAAGCTC
451 TAAATCGGGG GTCCTCTTAA GGGTTCGGAT TTAGTGCTTT ACGGCACCTC
501 GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG GGCCATCGCC
551 CTGATAGACG GTTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA
601 GTGGACTCTT GTTCCAAACT GGAACAACAC TCAACCCTAT CTCGGTCTAT
15  651 TCTTTTGATT TATAAGGGAT TTTGCCGATT TCGGCCTATT GGTAAAAAA
701 TGAGCTGATT TAACAAAAAT TTAACGCGAA TTTTAACAAA ATATTACGCT
751 TTACAATTTC AGGTGGCACT TTTGCGGGAA ATGTGCGCGG AATCCCTATT
801 TGTTTATTTT TCTAAATACA TTCAAATATG TATCCGCTCA TGAATTAATT
851 CTTAGAAAAA CTCATCGAGC ATCAAATGAA ACTGCAATTT ATTCATATCA
20  901 GGATTATCAA TACCATATTT TTGAAAAAGC CGTTTCTGTA ATGAAGGAGA
951 AAACTCACCG AGGCAGTTCC ATAGGATGGC AAGATCCTGG TATCGGTCTG
1001 CGATTCCGAC TCGTCCAACA TCAATACAAC CTATTAATTT CCCCTCGTCA
1051 AAAATAAGGT TATCAAGTGA GAAATCACCA TGAGTGACGA CTGAATCCGG
1101 TGAGAAATGGC AAAAGTTTAT GCATTTCTTT CCAGACTTGT TCAACAGGCC
25  1151 AGCCATTACG CTCGTCAATCA AAATCACTCG CATCAACCAA ACCGTTATTC
1201 ATTCTGATT GCGCCTGAGC GAGACGAAAT ACGCGATCGC TGTTAAAAGG
1251 ACAATTACAA ACAGGAATCG AATGCAACCG GCGCAGGAAC ACTGCCAGCG
1301 CATCAACAAT ATTTTCACCT GAATCAGGAT ATTCTTCTAA TACCTGGAAT
1351 GCTGTTTCC CGGGGATCGC AGTGGTGAGT AACCATGCAT CATCAGGAGT
30  1401 ACGGATAAAA TGCTTGATGG TCGGAAGAGG CATAAATTCG GTCAGCCAGT
1451 TTAGTCTGAC CATCTCATCT GTAACATCAT TGGCAACGCT ACCTTTGCCA
1501 TGTTTCAGAA ACAACTCTGG CGCATCGGGC TTCCCATACA ATCGATAGAT
1551 TGTCGCACCT GATTGCCCGA CATTATCGCG AGCCCATTTA TACCCATATA
1601 AATCAGCATC CATGTTGGAA TTTAATCGCG GCCTAGAGCA AGACGTTTCC
35  1651 CGTTGAATAT GGCTCATAAC ACCCCTTGTA TTAGTGTTTA TGTAAGCAGA
1701 CAGTTTATTT GTTCATGACC AAAATCCCTT AACGTGAGTT TTCGTTCCAC
1751 TGAGCGTCAG ACCCCGTAGA AAAGATCAAA GGATCTTCTT GAGATCCTTT
1801 TTTTCTGCGC GTAATCTGCT GCTTGCAAAC AAAAAACCA CCGCTACCAG
1851 CGGTGGTTTG TTTGCCGGAT CAAGAGCTAC CAACTCTTTT TCCGAAGGTA
40  1901 ACTGGCTTCA GCAGAGCGCA GATACCAAAT ACTGTCCTTC TAGTGTAGCC
1951 GTAGTTAGGC CACCACTTCA AGAACTCTGT AGCACCOCCT ACATACCTCG
2001 CTCTGCTAAT CCTGTTACCA GTGGCTGCTG CCAGTGGCGA TAAGTCGTGT
2051 CTTACCGGGT TGGACTCAAG ACGATAGTTA CCGGATAAGG CGCAGCGGTC
2101 GGGCTGAACG GGGGGTTCTG GCACACAGCC CAGCTTGGAG CGAACGACCT
45  2151 ACACCGAACT GAGATACCTA CAGCGTGAGC TATGAGAAAG CGCCACGCTT
2201 CCCGAAGGGA GAAAGGCGGA CAGGTATCCG GTAAGCGGCA GGGTCGGAAC
2251 AGGAGAGCGC ACGAGGGAGC TTCCAGGGGG AAACGCCTGG TATCTTTATA
2301 GTCCTGTCGG GTTTCGCCAC CTCTGACTTG AGCGTCGATT TTTGTGATGC
2351 TCGTCAGGGG GCGGGAGCCT ATGGAAAAAC GCCAGCAACG CGGCCTTTTT
50  2401 ACGGTTCCCTG GCCTTTTGCT GGCCTTTTGC TCACATGTTT TTTCTGCGT
2451 TATCCCTGA TTCTGTGGAT AACCGTATTA CCGCCTTTGA GTGAGCTGAT
2501 ACCGCTCGCC GCAGCCGAAC GACCGAGCGC AGCGAGTCAG TGAGCGAGGA
2551 AGCGGAAGAG CGCCTGATGC GGTATTTTCT CTTACGCAT CTGTGCGGTA
55  2601 TTTCACACCG CATATATGGT GCACTCTCAG TACAATCTGC TCTGATGCCG
2651 CATAGTTAAG CCAGTATACA CTCCGCTATC GCTACGTGAC TGGGTCATGG
2701 CTGCGCCCGG ACACCCGCCA ACACCCGCTG ACGCGCCCTG ACGGGCTTGT
2751 CTGCTCCCGG CATCCGCTTA CAGACAAGCT GTGACCGTCT CCGGGAGCTG
2801 CATGTGTCAG AGGTTTTTAC CGTCATCACC GAAACGCGCG AGGCAGCTGC
2851 GGTAAAGCTC ATCAGCGTGG TCGTGAAGCG ATTCACAGAT GTCTGCCTGT
60  2901 TCATCCGCGT CCAGCTCGTT GAGTTTCTCC AGAAGCGTTA ATGTCTGGCT

```

2951 TCTGATAAAG CGGGCCATGT TAAGGGCGGT TTTTTCCTGT TTGGTCACTG
 3001 ATGCCCTCCGT GTAAGGGGGA TTTCTGTTC A TGGGGGTAAT GATACCGATG
 3051 AAACGAGAGA GGATGCTCAC GATACGGGT ACTGATGATG AACATGCCCG
 3101 GTTACTGGAA CGTTGTGAGG GTAAACAAC T GCGGTATGG ATGCGGCGGG
 5 3151 ACCAGAGAAA AATCACTCAG GGTCAATGCC AGCGCTTCGT TAATACAGAT
 3201 GTAGGTGTTC CACAGGGTAG CCAGCAGCAT CCTGCGATGC AGATCCGGAA
 3251 CATAATGGTG CAGGGCGCTG ACTTCCGCGT TTCCAGACTT TACGAAACAC
 3301 GGAAACCGAA GACCATT CAT GTTGTGTGCT AGGTGCGAGA CGTTTTGCAG
 3351 CAGCAGTCGC TTCACGTTCT CTCGCGTATC GGTGATTCAT TCTGCTAACC
 10 3401 AGTAAGGCAA CCCC GCCAGC CTAGCCGGGT CCTCAACGAC AGGAGCACGA
 3451 TCATGCGCAC CCGTGGGGCC GCCATGCCCG CGATAATGGC CTGCTTCTCG
 3501 CCGAAACGTT TGGTGGCGGG ACCAGTGACG AAGGCTTGAG CGAGGGCGTG
 3551 CAAGATTCCG AATACCGCAA GCGACAGGCC GATCATCGTC GCGCTCCAGC
 3601 GAAAGCGGTC CTCGCCGAAA ATGACCCAGA GCGCTGCCGG CACCTGTCTT
 15 3651 ACGAGTTGCA TGATAAAGAA GACAGTCATA AGTGCGGCGA CGATAGTCAT
 3701 GCCCCGCGCC CACCGGAAGG AGCTGACTGG GTTGAAGGCT CTCAAGGGCA
 3751 TCGGTCGAGA TCCCGGTGCC TAATGAGTGA GCTAACTTAC ATTAATTGCG
 3801 TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT GCCAGTTGCA
 3851 TTAATGAATC GGCCAACGCG CGGGGAGAGG CGGTTTGCGT ATTGGGCGCC
 20 3901 AGGGTGGTTT TTCTTTTCAC CAGTGAGACG GGCAACAGCT GATTGCCCTT
 3951 CACCGCTGG CCCTGAGAGA GTTGACAGAA GCGGTCCACG CTGGTTTGCC
 4001 CCAGCAGGCG AAAATCCTGT TTGATGGTGG TTAACGGCGG GATATAACAT
 4051 GAGCTGTCTT CGGTATCGTC GTATCCCACT ACCGAGATAT CCGCACCAAC
 4101 GCGCAGCCCG GACTCGGTAA TGGCGCGCAT TGCGCCAGC GCCATCTGAT
 25 4151 CGTTGGCAAC CAGCATCGCA GTGGGAACGA TGCCCTCAT CAGCATTTCG
 4201 ATGGTTGTGTT GAAAACCGGA CATGGCACTC CAGTCGCCCT CCCGTTCCGC
 4251 TATCGGCTGA ATTTGATTGC GAGTGAGATA TTTATGCCAG CCAGCCAGAC
 4301 GCAGACGCGC CGAGACAGAA CTTAATGGGC CCGCTAACAG CGCGATTTCG
 4351 TGGTGACCCA ATGCGACCAG ATGCTCCACG CCCAGTCGCG TACCGTCTTC
 30 4401 ATGGGAGAAA ATAATACTGT TGATGGGTGT CTGGTCAGAG ACATCAAGAA
 4451 ATAACGCCGG AACATTAGTG CAGGCAGCTT CCACAGCAAT GGCATCCTGG
 4501 TCATCCAGCG GATAGTTAAT GATCAGCCCA CTGACGCGTT GCGCGAGAAG
 4551 ATTTGTCACC GCCGCTTAC AGGCTTCGAC GCCGCTTCGT TCTACCATCG
 4601 ACACCACCAC GCTGGCACC AGTTGATCGG CGCGAGATT AATCGCCGCG
 35 4651 ACAATTTGCG ACGGCGCGTG CAGGGCCAGA CTGGAGGTGG CAACGCCAAT
 4701 CAGCAACGAC TGTTTGCCCG CCAGTTGTTG TGCCACGCGG TTGGGAATGT
 4751 AATTCAGCTC CGCCATCGCC GCTTCCACTT TTTCCCGCGT TTTGCGAGAA
 4801 ACGTGGCTGG CCTGGTTCAC CACGCGGGAA ACGGTCTGAT AAGAGACACC
 4851 GGCATACTCT GCGACATCGT ATAACGTTAC TGGTTTCACA TTCACCACCC
 40 4901 TGAATTGACT CTCTTCGGG CGCTATCATG CCATACCGCG AAAGGTTTTG
 4951 CGCCATTCGA TGGTGTCCGG GATCTCGACG CTCTCCCTTA TGCGACTCCT
 5001 GCATTAGGAA GCAGCCAGT AGTAGGTTGA GGCCGTTGAG CACCGCCGCC
 5051 GCAAGGAATG GTGCATGCAA GGAGATGGCG CCAACAGTC CCGGCGCCAC
 5101 GGGGCCTGCC ACCATACCCA CGCCGAAACA AGCGCTCATG AGCCGAAGT
 45 5151 GCGGAGCCCG ATCTTCCCA TCGGTGATGT CGGCGATATA GCGCCAGCA
 5201 ACCGCACCTG TGGCGCCGGT GATGCCGCC ACGATGCGTC CGGCGTAGAG
 5251 GATCGAGATC TCGATCCCG GAAATTAATA CCACTACTA TAGGGGAATT
 5301 GTGAGCGGAT AACAATTCCC CTCTAGAAAT AATTTTGATT TAACTTTAAG
 5351 AAGGAGATAT ACCATGAAA

SEQUENCE LISTING 4

1 AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTTCATTAA
 51 TGCAGCTGGC ACGACAGGTT TCCCAGCTGG AAAGCGGGCA GTGAGCGCAA
 101 CGCAATTAAT GTGAGTTAGC TCACTCATT A GGCACCCAG GCTTTTACACT
 5 151 TTATGCTTCC GGCTCGTATG TTGTGTGGAA TTGTGAGCGG ATAACAATTT
 201 CACACAGGAA ACAGCTATGA CCATGATTAC GCCAAGCTTG CATGCCTGCA
 251 GGTGCACTCT AGAGGATCCC CGGGTACCGG TAGAAAAAAT GAGTAAAGGA
 301 GAAGAACTTT TCACTGGAGT TGTCCAATT CTTGTTGAAT TAGATGGTGA
 351 TGTTAATGGG CACAAATTTT CTGTCACTGG AGAGGGTGAA GGTGATGCAA
 10 401 CATACGGA AACTACCCTT AAATTTATTT GCACTACTGG AAAACTACCT
 451 GTTCCATGGC CAACACTTGT CACTACTTTC TCTTATGGTG TTCAATGCTT
 501 TTCCCGTTAT CCGGATCATA TGAAACGGCA TGACTTTTTT AAGAGTGCCA
 551 TGCCCGAAGG TTATGTACAG GAACGCACTA TATCTTTCAA AGATGACGGG
 601 AACTACAAGA CGCGTGCTGA AGTCAAGTTT GAAGGTGATA CCCTTGTTAA
 15 651 TCGTATCGAG TTTAAAGGTA TTGATTTTAA AGAAGATGGA AACATTCTCG
 701 GACACAAACT CGAGTACAAC TATAACTCAC ACAATGTATA CATCACGGCA
 751 GACAAACAAA AGAATGGAAT CAAAGCTAAC TTCAAAATTC GCCACAACAT
 801 TGAAGATGGA TCCGTTC AAC TAGCAGACCA TTATCAACAA AATACTCCAA
 851 TTGGCGATGG CCCTGTCTT TTACCAGACA ACCATTACCT GTCGACACAA
 20 901 TCTGCCCTT CGAAAGATCC CAACGAAAAG CGTGACCACA TGGTCCTTCT
 951 TGAGTTTGTA ACTGCTGCTG GGATTTACACA TGGCATGGAT GAGCTCTACA
 1001 AATAATGAAT TCCAAC TGAG CGCCGGTCGC TACCATTACC AACTTGTCTG
 1051 GTGTCAAAA TAATAGGCCT ACTAGTCGGC CGTACGGGCC CTTTCGCTCTC
 1101 GCGCGTTTTG GTGATGACGG TGAAACCTC TGACACATGC AGCTCCCGGA
 25 1151 ACGGTCACA GCTTGTCTGT AAGCGGATGC CGGGAGCAGA CAAGCCCGTC
 1201 AGGGCGCGTC AGCGGGTGTG GCGGGTGTG GGGGCTGGCT TAACATGCGC
 1251 GCATCAGAGC AGATTGTACT GAGAGTGCAC CATATGCGGT GTGAAATACC
 1301 GCACAGATGC GTAAGGAGAA AATACCGCAT CAGGCGGCCT TAAGGGCCTC
 1351 GTGATACGCC TATTTTTATA GGTTAATGTC ATGATAATAA TGGTTTCTTA
 30 1401 ACGTCAGGT GGCACCTTTC GGGGAAATGT GCGCGGAACC CCTATTGTCT
 1451 TATTTTTCTA AATACATTCA AATATGTATC CGCTCATGAG ACAATACCCC
 1501 TGATAAATGC TTCAATAATA TTGAAAAAGG AAGAGTATGA GTATTCAACA
 1551 TTTCCGTGTC GCCCTTATTC CCTTTTTTGC GGCATTTTGC CTTCTCTGTT
 1601 TTGCTCACCC AGAAACGCTG GTGAAAGTAA AAGATGCTGA AGATCAGTTG
 35 1651 GGTGCACGAG TGGGTTACAT CGAACTGGAT CTCAACAGCG GTAAGATCCT
 1701 TGAGAGTTTT CGCCCGAAG AACGTTTTCC AATGATGAGC ACTTTTAAAG
 1751 TTCTGCTATG TGGCGCGGTA TTATCCCGTA TTGACGCCGG GCAAGAGCAA
 1801 CTCGGTCGCC GCATACACTA TTCTCAGAAT GACTTGGTTG AGTACTCACC
 1851 AGTCACAGAA AAGCATCTTA CGGATGGCAT GACAGTAAGA GAATTATGCA
 40 1901 TGCTGCCAT AACCATGAGT GATAACACTG CGGCAACTT ACTTCTGACA
 1951 ACGATCGGAG GACCGAAGGA GCTAACCCTG TTTTTCACACA ACATGGGGGA
 2001 TCATGTAAC TCGCTTGATC GTTGGGAACC GGAGCTGAAT GAAGCCATAC
 2051 CAAACGACGA GCGTGACACC ACGATGCCCTG TAGCAATGGC AACAACGTTG
 2101 CGCAAACTAT TAACTGGCGA ACTACTTACT CTAGCTTCCC GGCAACAATT
 45 2151 AATAGACTGG ATGGAGGCGG ATAAAGTTGC AGGACCACTT CTGCGCTCGG
 2201 CCTTCCGGC TGGCTGGTTT ATTGCTGATA AATCTGGAGC CGGTGAGCGT
 2251 GGGTCTCGCG GTATCATTGC AGCACTGGGG CCAGATGGTA AGCCCTCCCG
 2301 TATCGTAGTT ATCTACACGA CGGGGAGTCA GGCAACTATG GATGAACGAA
 2351 ATAGACAGAT CGCTGAGATA GGTGCTCACA TGATTAAGCA TTGGTAACTG
 50 2401 TCAGACCAAG TTTACTCATA TATACTTTAG ATTGATTTAA AACTTCATTT
 2451 TTAATTTAAA AGGATCTAGG TGAAGATCCT TTTTGATAAT CTCATGACCA
 2501 AAATCCCTTA ACGTGAGTTT TCGTTCCACT GAGCGTCAGA CCCCCTAGAA
 2551 AAGATCAAAG GATCTTCTTG AGATCCTTTT TTTCTGCGCG TAATCTGCTG
 2601 CTGCAAAACA AAAAAACCAG CGCTACCAGG GGTGGTTTGT TTGCCGGATC
 55 2651 AAGAGCTACC AACTCTTTT CCGAAGGTAA CTGGCTTCAG CAGAGCGCAG
 2701 ATACCAAATA CTGTCTTCT AGTGTAGCCG TAGTTAGGCC ACCATTCAA
 2751 GAACTCTGTA GCACCGCCTA CATACCTCGC TCTGCTAATC CTGTTACCAG
 2801 TGGCTGCTGC CAGTGGCGAT AAGTCGTGTC TTACCGGGTT GGACTCAAGA
 2851 CGATAGTTAC CGGATAAGGC GCAGCGGTG GGTGAACGG GGGGTTCTGT
 60 2901 CACACAGCCC AGCTTGAGC GAACGACCTA CACCGAAGT AGATACCTAC

5 2951 AGCGTGAGCT ATGAGAAAGC GCCACGCTTC CCGAAGGGAG AAAGGCGGAC
3001 AGGTATCCGG TAAGCGGCAG GGTCGGAACA GGAGAGCGCA CGAGGGAGCT
3051 TCCAGGGGGA AACGCCTGGT ATCTTTATAG TCCTGTCGGG TTTCGCCACC
3101 TCTGACTTGA GCGTCGATT TTGTGATGCT CGTCAGGGGG GCGGAGCCTA
3151 TGGAAAAACG CCAGCAACGC GGCCTTTTTC CGGTTCTCTG CCTTTTGCTG
3201 GCCTTTTGCT CACATGTTCT TTCCTGCGTT ATCCCCTGAT TCTGTGGATA
3251 ACCGTATTAC CGCCTTTGAG TGAGCTGATA CCGCTCGCCG CAGCCGAACG
3301 ACCGAGCGCA GCGAGTCAGT GAGCGAGGAA GCGGAAG

SEQUENCE LISTING 5

1 ATGAAACATC ACCATCACCA TCACCCCATG AGCGATTACG ACATCCCCAC
 51 TACTGAGAAT CTTTATTTTC AGGGCGCCAT GGGAGGCACG GTACCGGTAG
 101 AAAAAATGAG TAAAGGAGAA GAACTTTTCA CTGGAGTTGT CCAATTCTT
 5 151 GTTGAATTAG ATGGTGATGT TAATGGGCAC AAATTTTCTG TCAGTGGAGA
 201 GGGTGAAGGT GATGCAACAT ACGGAAAAC TACCCTTAAA TTTATTTGCA
 251 CTACTGGAAA ACTACCTGTT CCATGGCCAA CACTTGTCAC TACTTTCTCT
 301 TATGGTGTTT AATGCTTTTC CCGTTATCCG GATCATATGA AACGGCATGA
 351 CTTTTTCAAG AGTGCCATGC CCGAAGGTTA TGTACAGGAA CGCACTATAT
 10 401 CTTTCAAAGA TGACGGGAAC TACAAGACGC GTGCTGAAGT CAAGTTTGAA
 451 GGTGATACCC TTGTTAATCG TATCGAGTTA AAAGGTATTG ATTTTAAAGA
 501 AGATGGAAAC ATTCTCGGAC ACAAACTCGA GTACAACTAT AACTCACACA
 551 ATGTATACAT CACGGCAGAC AAACAAAAGA ATGGAATCAA AGCTAACTTC
 601 AAAATTGCGC ACAACATTGA AGATGGATCC GTTCAACTAG CAGACCATTA
 15 651 TCAACAAAAT ACTCCAATTG GCGATGGCCC TGTCTTTTTC CCAGACAACC
 701 ATTACCTGTC GACACAATCT GCCCTTTCGA AAGATCCCAA CGAAAAGCGT
 751 GACCACATGG TCCTTCTTGA GTTTGTAAC TCTGCTGGGA TTACACATGG
 801 CATGGATGAG CTCGTCGAC AAGCTTGCGG CCGCACTCGA GCACCACCAC
 851 CACCACCACT GAGATCCGGC TGCTAACAAA GCCCGAAAGG AAGCTGAGTT
 20 901 GGCTGCTGCC ACCGCTGAGC AATAACTAGC ATAACCCCTT GGGGCTCTA
 951 AACGGGTCTT GAGGGGTTTT TTGCTGAAAG GAGGAACTAT ATCCGGATTG
 1001 GCGAATGGGA CGCGCCCTGT AGCGGCGCAT TAAGCGCGGC GGGTGTGGTG
 1051 GTTACGCGCA GCGTGACCGC TAACTTGCC AGCGCCCTAG CGCGCCCTCC
 1101 TTTGCTTTTC TTCCCTTCCT TTCTCGCCAC GTTCGCGGC TTTCCCGTCC
 25 1151 AAGCTCTAAA TCGGGGGCTC CCTTTAGGGT TCCGATTAG TGCTTTACGG
 1201 CACCTCGACC CCAAAAAC TGAATAGGGT GATGGTTAC GTAGTGGGCC
 1251 ATCGCCCTGA TAGACGGTTT TTCGCCCTTT GACGTGGAG TCCACGTCTC
 1301 TTAATAGTGG ACTCTGTTC CAACTGGAA CAACACTCAA CCTATCTCG
 1351 GTCTATTCTT TTGATTTATA AGGGATTTTG CCGATTTCGG CCTATTGGTT
 30 1401 AAAAAATGAG CTGATTTAAC AAAAAATTAA CGCGAATTTT AACAAAATAT
 1451 TAACGTTTAC AATTTAGGT GGCACTTTTC GGGGAAATGT GCGCGGAACC
 1501 CCTATTTGTT TATTTTCTA AATACATTCA AATATGTATC CGCTCATGAA
 1551 TTAATTCTTA GAAAACTCA TCGAGCATCA AATGAAACTG CAATTTATTC
 1601 ATATCAGGAT TATCAATACC ATATTTTGA AAAAGCCGTT TCTGTAATGA
 35 1651 AGGAGAAAAC TCACCGAGGC AGTTCCATAG GATGGCAAGA TCCTGGTATC
 1701 GGTCTGCGAT TCCGACTCGT CCAACATCAA TACAACCTAT TAATTTCCCC
 1751 TCGTCAAAAA TAAGGTATC AAGTGAGAAA TCACCATGAG TGACGACTGA
 1801 ATCCGGTGAG AATGGCAAAA GTTTATGCAT TTCTTTCCAG ACTTTATTC
 1851 CAGGCCAGCC ATTACGCTCG TCATCAAAAT CACTCGCATC AACCAAACCG
 40 1901 TTATTCATTC GTGATTGCGC CTGAGCGAGA CGAAATACGC GATCGCTGTT
 1951 AAAAGGACAA TTACAACAG GAATCGAATG CAACCGCGC AGGAACACTG
 2001 CCAGCGCATC AACAATATTT TCACCTGAAT CAGGATATTC TTCTAATACC
 2051 TGAATGCTG TTTTCCCGGG GATCGCAGTG GTGAGTAACC ATGCATCATC
 2101 AGGAGTACGG ATAAAATGCT TGATGGTCGG AAGAGGCATA AATTCGGTCA
 45 2151 GCCAGTTTAG TCTGACCATC TCATCTGTAA CATCATGGC AACGCTACCT
 2201 TTGCCATGTT TCAGAAACAA CTCTGGCGCA TCGGGCTTCC CATACAATCG
 2251 ATAGATTGTC GCACCTGATT GCCCGACATT ATCGCGAGCC CATTTATACC
 2301 CATATAAATC AGCATCCATG TTGGAATTTA ATCGCGGCCT AGAGCAAGAC
 2351 GTTTCCTGTT GAATATGGCT CATAACACCC CTTGTATTAC TGTTTATGTA
 50 2401 AGCAGACAGT TTTATTGTTT ATGACCAAAA TCCCTTAACG TGAGTTTTCG
 2451 TTCCACTGAG CGTCAGACCC CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA
 2501 TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT GCAAACAAAA AAACCACCGC
 2551 TACCAGCGGT GGTTTGTTTG CCGGATCAAG AGCTACCAAC TCTTTTCCG
 2601 AAGGTAAGTG GCTTCAGCAG AGCGCAGATA CCAAATACTG TCCTTCTAGT
 55 2651 GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA CCGCCTACAT
 2701 ACCTCGCTCT GCTAATCTG TTACCAGTGG CTGCTGCCAG TGGCGATAAG
 2751 TCGTGTCTTA CCGGGTTGGA CTCAAGACGA TAGTTACCGG ATAAGGCGCA
 2801 GCGGTCGGGC TGAACGGGGG GTTCGTGCAC ACAGCCGAGC TTGGAGCGAA
 2851 CGACCTACAC CGAACTGAGA TACCTACAGC GTGAGCTATG AGAAAGCGCC
 60 2901 ACGCTTCCCG AAGGGAGAAA GCGGACAGG TATCCGGTAA GCGGAGGGT
 2951 CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAC GCCTGGTATC

	3001	TTTATAGTCC	TGTCGGGTTT	CGCCACCTCT	GACTTGAGCG	TCGATTTTGT
	3051	TGATGCTCGT	CAGGGGGGCG	GAGCCTATGG	AAAAACGCCA	GCAACGCGGC
	3101	CTTTTACGG	TTCTTGGCCT	TTTGCTGGCC	TTTGCTCAC	ATGTTCTTTC
5	3151	CTGCGTTATC	CCCTGATTCT	GTGGATAACC	GTATTACCGC	CTTGAGTGA
	3201	GCTGATACCG	CTCGCCGCAG	CCGAACGACC	GAGCGCAGCG	AGTCAGTGAG
	3251	CGAGGAAGCG	GAAGAGCGCC	TGATGCGGTA	TTTTCTCCTT	ACGCATCTGT
	3301	GCGGTATTTT	ACACCGCATA	TATGGTGCAC	TCTCAGTACA	ATCTGCTCTG
	3351	ATGCCGCATA	GTTAAGCCAG	TATACACTCC	GCTATCGCTA	CGTGACTGGG
	3401	TCATGGCTGC	GCCCCGACAC	CCGCCAACAC	CCGCTGACGC	GCCCTGACGG
10	3451	GCTTGTCTGC	TCCC GG CATC	CGCTTACAGA	CAAGCTGTGA	CCGTCTCCGG
	3501	GAGCTGCATG	TGTCAGAGGT	TTTCACCGTC	ATCACCGAAA	CGCGCGAGGC
	3551	AGCTGCGGTA	AAGCTCATCA	GCGTGGTCGT	GAAGCGATTG	ACAGATGTCT
	3601	GCCTGTTTCA	CCGCGTCCAG	CTCGTTGAGT	TTCTCCAGAA	GCGTTAATGT
	3651	CTGGCTTCTG	ATAAAGCGGG	CCATGTTAAG	GGCGGTTTTT	TCCTGTTTGG
15	3701	TCACTGATGC	CTCCGTGTAA	GGGGGATTTC	TGTTTATGGG	GTTAATGATA
	3751	CCGATGAAAC	GAGAGAGGAT	GCTCACGATA	CGGGTTACTG	ATGATGAACA
	3801	TGCCCCGTTA	CTGGAACGTT	GTGAGGGTAA	ACAACCTGGCG	GTATGGATGC
	3851	GGCGGGACCA	GAGAAAAATC	ACTCAGGGTC	AATGCCAGCG	CTTCGTTAAT
	3901	ACAGATGTAG	GTGTTCCACA	GGGTAGCCAG	CAGCATCTTG	CGATGCAGAT
20	3951	CCGGAACATA	ATGGTGCAGG	GCGCTGACTT	CCGCGTTTCC	AGACTTTACG
	4001	AAACACGGAA	ACCGAAGACC	ATTCATGTTG	TTGCTCAGGT	CGCAGACGTT
	4051	TTGCAGCAGC	AGTCGCTTCA	CGTTCGCTCG	CGTATCGGTG	ATTCATTCTG
	4101	CTAACCAGTA	AGGCAACCCC	GCCAGCCTAG	CCGGGTCTCT	AACGACAGGA
	4151	GACGATCAT	GCGCACCCGT	GGGGCCGCCA	TGCCGGCGAT	AATGGCCTGC
25	4201	TTCTCGCCGA	AACGTTTGGT	GGCGGGACCA	GTGACGAAGG	CTTGAGCGAG
	4251	GGCGTGCAAG	ATTCCGAATA	CCGCAAGCGA	CAGGCCGATC	ATCGTCGCGC
	4301	TCCAGCGAAA	GCGGTCTCTG	CCGAAAATGA	CCCAGAGCGC	TGCCGGCACC
	4351	TGTCCTACGA	GTTGCATGAT	AAAGAAGACA	GTCATAAGTG	CGGCGACGAT
	4401	AGTCATGCCC	CGCGCCCACC	GGAAGGAGCT	GACTGGGTTG	AAGGCTCTCA
30	4451	AGGGCATCGG	TGCAGATCCC	GGTGCTAAT	GAGTGAGCTA	ACTTACATTA
	4501	ATTGCGTTGC	GCTCACTGCC	CGCTTTCCAG	TCGGGAAACC	TGTCGTGCCA
	4551	GCTGCATTAA	TGAATCGGCC	AACGCGCGGG	GAGAGGCGGT	TTGCGTATTG
	4601	GGCGCCAGGG	TGGTTTTTCT	TTTCACCACT	GAGACGGGCA	ACAGCTGATT
	4651	GCCCTTACCC	GCCTGGCCCT	GAGAGAGTTG	CAGCAAGCGG	TCCACGCTGG
35	4701	TTTGCCCCAG	CAGGCGAAAA	TCCTGTTTGA	TGGTGTTTAA	CGGCGGGATA
	4751	TAACATGAGC	TGTCTTCGGT	ATCGTCGTAT	CCCACTACCG	AGATATCCGC
	4801	ACCAACGCGC	AGCCCGGACT	CGGTAATGGC	GCGCATTTGG	CCCAGCGCCA
	4851	TCTGATCGTT	GGCAACCAGC	ATCGCAGTGG	GAACGATGCC	CTCATTACGC
	4901	ATTTGTCATG	TTTGTTGAAA	ACCGGACATG	GCACTCCAGT	CGCTTCCCG
40	4951	TTCCGCTATC	GGCTGAATTT	GATTGCGAGT	GAGATATTTA	TGCCAGCCAG
	5001	CCAGACGCAG	ACGCGCCGAG	ACAGAACTTA	ATGGGCCCCG	TAACAGCGCG
	5051	ATTTGCTGGT	GACCCAATGC	GACCAGATGC	TCCACGCCCA	GTCGCGTACC
	5101	GTCTTCATGG	GAGAAAATAA	TACTGTTGAT	GGGTGTCTGG	TCAGAGACAT
	5151	CAAGAAATAA	CGCCGGAACA	TTAGTGCAAG	CAGCTTCCAC	AGCAATGGCA
45	5201	TCCTGGTCAT	CCAGCGGATA	GTTAATGATC	AGCCCACTGA	CGCGTTGCGC
	5251	GAGAAGATTG	TGCACCGCCG	CTTTACAGGC	TTGACGCGCG	CTTCGTTCTA
	5301	CCATCGACAC	CACCACGCTG	GCACCCAGTT	GATCGGCGCG	AGATTTAATC
	5351	GCCGCGACAA	TTTGCGACGG	CGCGTGACGG	GCCAGACTGG	AGGTGGCAAC
	5401	GCCAATCAGC	AACGACTGTT	TGCCCCGCCAG	TTGTTGTGCC	ACGCGGTTGG
50	5451	GAATGTAATT	CAGCTCCGCC	ATCGCCGCTT	CCACTTTTTT	CCGCGTTTTT
	5501	GCAGAAACGT	GGCTGGCCCT	GTTCAACACG	CGGGAAACGG	TCTGATAAGA
	5551	GACACCGGCA	TACTCTGCGA	CATCGTATAA	CGTTACTGGT	TTACATTTCA
	5601	CCACCCTGAA	TTGACTCTCT	TCCGGGCGCT	ATCATGCCAT	ACCGCGAAAG
	5651	GTTTTTGCGC	ATTTCGATGG	GTCCGGGATC	TCGACGCTCT	CCCTTATGCG
55	5701	ACTCCTGCAT	TAGGAAGCAG	CCCAGTAGTA	GGTTGAGGCC	GTTGAGCACC
	5751	GCCGCCGCAA	GGAATGGTGC	ATGCAAGGAG	ATGGCGCCCA	ACAGTCCCCC
	5801	GGCCACGGGG	CCTGCCACCA	TACCCACGCC	GAAACAAGCG	CTCATGAGCC
	5851	CGAAGTGGCG	AGCCCCGATC	TCCCCATCGG	TGATGTCGGC	GATATAGCCG
	5901	CCAGCAACCG	CACCTGTGGC	GCCGGTGATG	CCGCCCACGA	TGCGTCCGGC
60	5951	GTAAGAGGATC	GAGATCTCGA	TCCCGCGAAA	TTAATACGAC	TCACTATAGG
	6001	GGAATTGTGA	GCGGATAACA	ATTCCTCTCT	AGAAATAATT	TTGATTTAAC
	6051	TTTAAGAAGG	AGATATACC			

CLAIMS

- 1) Circular recombinant plasmid DNA construct encoding a) a protein tag, b) a visual marker protein, and containing c) a multiple cloning site suitable for insertion of an additional gene, characterised in that the gene sequence encoding the protein tag and the visual marker protein are specifically designed and engineered at the DNA level for respectively a) immobilisation purposes and b) visualisation and quantification purposes at the protein level.
- 2) Construct according to claim 1, characterised in that the protein tag is chosen from the group containing lysine (lys), histidine (his), tyrosine (tyr), phenylalanine (phe), arginine (arg), glutamic acid (glu), aspartic acid (asp), glutamate, aspartate, asparagine (asn), glycine (gly), glutamine (gln), alanine (ala), valine (val), tryptophan (trp).
- 3) Construct according to claim 1 or 2, characterised in that the protein tag is a histidine-tag such as a polyhistidine variant, in particular (6X) histidine.
- 4) Construct according to any one of the preceding claims, characterised in that the visual marker protein is chosen from the group containing fluorescent or phosphorescent proteins.
- 5) Construct according to claim 4, characterised in that the fluorescent protein is chosen from the group containing Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP), Yellow Fluorescent Protein (YFP) and Blue Fluorescent Protein (BFP) as well as their variants and/or mutants.
- 6) Construct according to any one of the preceding claims, characterised in that the multiple cloning site contains restriction enzyme recognition sites.
- 7) Construct according to claim 6, characterised in that the restriction enzyme recognition site is chosen from the group containing SacI, Sal I, Hind III, Eag I, Not I.
- 8) Construct according to any one of the preceding claims, characterised in that it further contains a frame adapter of variable length between the visual marker and protein tag genes.
- 9) Protein expressed by circular recombinant plasmid DNA construct according to any one of claims 1 to 8, characterised in that in the MCS adjacent to the visual marker, it further contains an additional target protein and in that the tag is suitable to interact directly with appropriate surface pendant groups of a support material.
- 10) Protein according to claim 9 characterised in that it is a fusion protein.

- 11) Use of the protein constructs of claim 9 or 10, in immobilisation and visualisation of proteins on compatible support material.
- 12) Method for preparing and immobilising a protein on a support material, characterised in that it contains the steps of:
- 5 a) Engineering at the DNA level, in series a protein tag suitable to interact directly with appropriate surface pendant groups of a support material, a fluorescent marker protein for visualisation and quantification purposes at the protein level and a multiple cloning site suitable for insertion of a target protein to be immobilised,
- 10 b) Inserting the corresponding gene of the target protein to be immobilised into the multiple cloning site;
- c) Initiating protein expression.
- d) Optionally pre-treating the support material;
- e) Incubating the protein and support material together, wherein the protein is
- 15 immobilised to the support via specific tag-surface interactions;
- f) Washing away the non-specific biomolecules;
- g) Optionally quantifying the fluorescence of the visual marker protein;
- h) Optionally desorbing the target protein.
- 13) Method according to claim 12, characterised in that the support material is chosen
- 20 from the group containing polymers, biopolymers, glass and composites containing silicone dioxides, metals and metal oxides, as well as any combination thereof on the microscopic, mesoscopic or macroscopic length scale.
- 14) Method according to any one of claims 12 and 13, characterised in that the support material is chosen from the group containing polymers, silicon dioxides, aluminum
- 25 oxides, titanium oxides, magnesium oxides, borates, metals and other metal oxides.
- 15) Method according to any one of claims 13 and 14, characterised in that the polymers are chosen from the group containing polyolefins such as polystyrene, polyacrylates, polymethacrylates, polybutylene, polyvinylalcohol and related
- 30 derivatives, polyvinylchlorides, polyisoprene, polypropylene, polyphenols, polyamides, polyesters polysulfones, polyethersulfones, polyethersulfides, polyimines, polyethyleneglycols, polypropyleneglycols, polyimides, polycarbonates, polyurethanes,

- 16) Method according to claim 15, characterised in that the polymer surface is chemically treated to bear various functional groups chosen between carboxyl groups, hydroxyl groups, amino groups, amide groups, ester groups, imide groups, imine groups, mercapto groups, nitro groups, sulfonate groups, phosphate groups, phosphonate groups, cyano groups, sulfone groups, aldehyde groups, epoxide groups, urethane groups, ketone groups, phenolic groups, aromatic groups, alkyl, alkenyl, alkynyl, acyl and aryl groups, silanol groups, silicon oxide groups, siloxane groups, metal hydroxide groups, metal oxide groups, and elemental metals.
- 17) Method according to any one of claims 13 to 16, characterised in that the support material is carboxylated polystyrene.
- 18) Immobilised protein construct obtained by the method according to any one of claims 13 to 17, characterised in that it is covalently or non-covalently bonded to the support material.
- 19) Immobilised protein construct according to claim 18, characterised in that it is non-covalent and yet freely accessible and leach-free like proteins immobilised in the covalent sense.
- 20) Use of the immobilised protein constructs according to any one of claims 18 and 19 in applications selected from analysis, diagnosis (like in enzyme based diagnostic kits), incubation, storage, sensing, arraying and orienting, catalysis, stabilisation, binding, signal transduction, chemical transformation, implant passivation and surface biocompatibilization, surface activation, purification, detoxification and scavenging.

**[Received by the International Bureau on 04 DEC 2003 (04.12.03) ;
original claims 1 to 3, unchanged ; original claims 4 to 16, amended ;
claims 17 to 20, cancelled]**

- 1) Circular recombinant plasmid DNA construct encoding a) a protein tag,
b) a visual marker protein, and containing c) a multiple cloning site suitable for
insertion of an additional gene, characterised in that the gene sequence encoding
the protein tag and the visual marker protein are specifically designed and
engineered at the DNA level for respectively a) immobilisation purposes and
b) visualisation and quantification purposes at the protein level.
- 2) Construct according to claim 1, characterised in that the protein tag is chosen from
the group containing lysine (lys), histidine (his), tyrosine (tyr), phenylalanine (phe),
arginine (arg), glutamic acid (glu), aspartic acid (asp), glutamate, aspartate,
asparagine (asn), glycine (gly), glutamine (gln), alanine (ala), valine (val),
tryptophan (trp).
- 3) Construct according to claim 1 or 2, characterised in that the protein tag is a
histidine-tag such as a polyhistidine variant, in particular (6X) histidine.
- 4) Construct according to any one of the preceding claims, characterised in that the
visual marker protein is chosen from the group containing fluorescent or
phosphorescent proteins, wherein the fluorescent protein is chosen from the group
containing Green Fluorescent Protein (GFP), Red Fluorescent Protein (RFP),
Yellow Fluorescent Protein (YFP) and Blue Fluorescent Protein (BFP) as well as
their variants and/or mutants.
- 5) Construct according to any one of the preceding claims, characterised in that the
multiple cloning site contains restriction enzyme recognition sites chosen from the
group containing SacI, Sal I, Hid III, Eag I, Not I.
- 6) Construct according to any one of the preceding claims, characterised in that it
further contains a frame adapter of variable length between the visual marker and
protein tag genes.
- 7) Construct according to any one of the preceding claims, characterised in that it
expresses a fusion protein, wherein the tag is suitable to interact directly with
appropriate surface pendant groups of a support material.
- 8) Construct according to claim 9, characterised in that the direct interaction with the
support material is covalent or non-covalent.
- 9) Construct according to claim 10, characterised in that the direct interaction is non-
covalent and yet freely accessible and leach-free like covalent one.

- 10) Method for preparing and immobilising a protein on a support material, characterised in that it contains the steps of:
- 5 a) Engineering at the DNA level, in series a protein tag suitable to interact directly with appropriate surface pendant groups of a support material, a fluorescent marker protein for visualisation and quantification purposes at the protein level and a multiple cloning site suitable for insertion of a target protein to be immobilised,
 - b) Inserting the corresponding gene of the target protein to be immobilised into the multiple cloning site;
 - 10 c) Initiating protein expression.
 - d) Optionally pre-treating the support material;
 - e) Incubating the protein and support material together, wherein the protein is immobilised to the support via specific tag-surface interactions;
 - f) Washing away the non-specific biomolecules;
 - 15 g) Optionally quantifying the fluorescence of the visual marker protein;
 - h) Optionally desorbing the target protein.
- 11) Method according to claim 10, characterised in that the support material is chosen from the group containing polymers, biopolymers, glass and composites containing silicone dioxides, metals and metal oxides, as well as any combination thereof on the microscopic, mesoscopic or macroscopic length scale.
- 20 12) Method according to any one of claims 10 and 11, characterised in that the support material is chosen from the group containing polymers, silicon dioxides, aluminum oxides, titanium oxides, magnesium oxides, borates, metals and other metal oxides.
- 25 13) Method according to any one of claims 11 and 12, characterised in that the polymers are chosen from the group containing polyolefins such as polystyrene, polyacrylates, polymethacrylates, polybutylene, polyvinylalcohol and related derivatives, polyvinylchlorides, polyisoprene, polypropylene, polyphenols, polyamides, polyesters polysulfones, polyethersulfones, polyethersulfides,
- 30 polyimines, polyethyleneglycols, polypropyleneglycols, polyimides, polycarbonates, polyurethanes,

- 14) Method according to claim 13, characterised in that the polymer surface is chemically treated to bear various functional groups chosen between carboxyl groups, hydroxyl groups, amino groups, amide groups, ester groups, imide groups, imine groups, mercapto groups, nitro groups, sulfonate groups, phosphate groups, phosphonate groups, cyano groups, sulfone groups, aldehyde groups, epoxide groups, urethane groups, ketone groups, phenolic groups, aromatic groups, alkyl, alkenyl, alkynyl, acyl and aryl groups, silanol groups, silicon oxide groups, siloxane groups, metal hydroxide groups, metal oxide groups, and elemental metals.
- 15) Method according to any one of claims 13 to 16, characterised in that the support material is carboxylated polystyrene.
- 16) Method according to claim 10, characterised in that quantifying in step g) of the fluorescence of the visual marker protein is used in applications selected from analysis, diagnosis (like in enzyme based diagnostic kits), incubation, storage, sensing, arraying and orienting, catalysis, stabilisation, binding, signal transduction, chemical transformation, implant passivation and surface biocompatibilization, surface activation, purification, detoxification and scavenging.




Fig. 1

10/550226

2/7




Fig. 2




Fig. 3




Fig. 4

5/7




Fig. 5




Fig. 6




Fig. 7

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.